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Abstract 
 
Malignant melanoma is the most deadly skin cancer. Clinical studies reported a dramatic 
increase in the incidence of melanoma over the past few years. A very distinctive feature 
of melanoma is its high degree of heterogeneity and cellular plasticity. Within the tumor 
there are different genetically defined subpopulations of melanoma cells, which is one of 
the reasons for the low efficacy of targeted therapies. Furthermore, most melanomas 
quickly develop a resistance to these therapies, causing tumor relapse. For all these 
reasons, gaining an understanding of the molecular and cellular mechanisms driving 
melanoma progression will be important for developing potent therapeutic approaches. 
So far, some key regulatory pathways normally activated in melanoma have been well 
defined, and these pathways are mainly driven by activation of oncogenes like BRAF 
and NRAS, with a considerable relevance for clinical practice. However, the 
identification of novel key regulators and pathways is still a challenge and will help to 
better understand melanoma development and to open up new possibilities to treat 
therapy resistant tumors.  
Recent studies and work previously conducted in our laboratory reported that the 
histone methyltransferase SETDB1 plays a major role in melanoma pathogenesis. It has 
been observed that SETDB1 expression, which correlates with its amplification state in 
melanoma, is also associated with melanoma progression. However, the role of 
SETDB1 and its mode of action in melanoma are still unclear.  
The aim of this project is to clarify the role of SETDB1 in melanoma, through the 
identification and functional characterization of SETDB1-mediated molecular 
mechanisms. Here, I report that SETDB1 expression caused deep changes in 
melanoma transcriptome resulting in the deregulation of pro- and anti-tumorigenic 
factors. Specifically, SETDB1 induced THBS1 upregulation and suppressed DCT 
expression. SETDB1 functions are dependent on its catalytic SET domain. During 
melanoma progression, SETDB1 promoted important epigenetic alterations such as 
changing the genomic distribution of H3K9me3 and H3K4me1 marks. These histone 
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modifications impacted the transcription of SETDB1 downstream targets. I could show 
that melanoma cells were sensitive to treatment with the SETDB1-inhibitor mithramycin 
A. Mithramycin treatment suppressed SETDB1 expression and tumorigenic properties of 
melanoma cells. Combinatorial treatment with mithramycin and MAPK inhibitors showed 
enhanced anti-tumor effects. 
Taken together, the findings presented here highlight the crucial functional and 
mechanistic role of SETDB1 in melanoma. SETDB1 could be considered as a potential 
future target for the treatment of melanoma. 
 
Zusammenfassung 
 
Das maligne Melanom ist die tödlichste Form von Hautkrebs. Klinische Studien haben 
einen drastischen Anstieg von Melanomerkrankungen in den letzten Jahren festgestellt. 
Ein grundlegendes Merkmal des Melanoms ist sein hoher Grad an Heterogenität und 
zellulärer Plastizität. Innerhalb eines Tumors lassen sich verschiedene genetisch-
definierte Subpopulationen von Melanomzellen finden, die eine effiziente zielgerichtete 
Krebstherapie erschweren. Darüber hinaus führt die schnelle Ausbildung von 
Resistenzen gegen zielgerichtete Therapien zu Rezidiven. Daher ist es wichtig, die 
molekularen und zellulären Mechanismen der Melanomprogression genauer zu 
untersuchen, um einen wirkungsvollen therapeutischen Ansatz zu finden. Es wurden 
bereits einige wichtige regulatorische Signalwege beschrieben, die in Melanomen 
aktiviert sind. Diese Signalwege werden hauptsächlich durch die beiden Onkogene 
BRAF sowie NRAS aktiviert, was von hoher klinischer Relevanz für die Auswahl einer 
geeigneten Therapiemethode ist. Eine große Herausforderung stellt jedoch die 
Identifikation von weiteren in der Melanomentstehung wichtigen Schlüsselregulatoren 
und Signalwegen dar. Dies ist wichtig, um die Entwicklung des Melanoms genauer zu 
verstehen um so in Zukunft therapieresistente Melanome behandeln zu können.  
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Kürzlich veröffentlichte Studien und Vorarbeiten aus unserem Labor haben gezeigt, 
dass die Histon-Methyltransferase SETDB1 eine wichtige Rolle in der 
Melanompathogenese spielt. Es wurde herausgefunden, dass die Expression von 
SETDB1, die im Melanom mit dem Amplifikationsstatus korreliert, mit einem 
Voranschreiten des Melanoms assoziiert ist. Jedoch ist die genaue Rolle und Funktion 
von SETDB1 bis heute unklar.  
Das Ziel dieser Doktorarbeit bestand darin, die Rolle von SETDB1 im Melanom anhand 
der Identifizierung und funktionellen Charakterisierung der von SETDB1 vermittelten 
molekularen Mechanismen zu untersuchen. In dieser Arbeit wird gezeigt, dass die 
Expression von SETDB1 tiefgreifende Veränderungen des Melanomtranskriptoms nach 
sich zog und damit einen großen Einfluss auf die Regulation von pro- und anti-
tumorigenen Faktoren hatte. Im Einzelnen induzierte SETDB1 die Expression von 
THBS1 und unterdrückte die Expression von DCT. Zudem ging die Expression von 
SETDB1 mit einer erhöhten Sekretion melanomzellspezifischer Onkoproteine einher. 
Die Funktionen von SETDB1 waren abhängig von der Aktivität seiner katalytischen SET 
Domäne. Während der Melanomprogression veranlasste SETDB1 wichtige 
epigenetische Modifizierungen, wie die Veränderung der genomischen Verteilung von 
H3K9 Trimethylierungen und H3K4 Monomethylierungen. Diese Histonmodifikationen 
wirkten sich auf die Transkription von Downstream-Faktoren von SETDB1 aus. 
Weiterhin konnte ich zeigen, dass Melanomzellen sensitiv gegenüber der Behandlung 
mit dem SETDB1-Inhibitor Mithramycin A waren. Die Behandlung mit Mithramycin 
unterdrückte die Expression von SETDB1 und damit dessen krebsfördernde 
Eigenschaften in Melanomzellen. Eine Kombinationstherapie mit Mithramycin und 
MAPK-Inhibitoren erzielte einen erhöhten antitumorigene Effekt.  
Zusammengefasst zeigen die Ergebnisse dieser Studie, dass SETDB1 eine 
entscheidende funktionelle und mechanistische Rolle im Melanom spielt. SETDB1 
könnte daher als potentieller Angriffspunkt für zukünftige Melanomtherapien in Betracht 
gezogen werden.  
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1 Introduction 
 
1.1 Malignant melanoma 
 
1.1.1 Epidemiology and risk factors 
Malignant melanoma is the most common and lethal skin neoplasia. According to the 
worldwide cancer statistics provided by the Global Cancer Observatory (Bray et al, 
2018), in 2018 almost 300.000 new cases of melanoma and more than 60.000 deaths 
were estimated, confirming the remarkable increasing trend observed over the last years 
(Leiter et al, 2014) (Whiteman et al, 2016). Several main risk factors have been defined 
for melanoma. The most known and well-characterized is represented by the exposure 
to UV radiation (UVR), which induces profound genetic and biological changes linked to 
malignant transformation of cells (Watson et al, 2016). UVR DNA damages mostly occur 
in light-skinned people and people with a genetic susceptibility (Gloster & Neal, 2006) 
(Ferguson et al, 2019). While the sporadic cases are the most frequent, familial 
melanomas represent about 10% of the total cases per year (Soura et al, 2016). 
 
1.1.2 Melanoma development and progression model 
Malignant melanomas arise from melanocytes, which are melanin pigment-synthesizing 
cells found in the skin and in several other anatomical sites, such as eyes, mucosa, 
inner ear, nervous system, and heart (Cichorek et al, 2013). Melanin produced by 
melanocytes is delivered to neighboured keratinocytes and serves as skin protection 
system to UVR.  
Melanocytic transformation is accompanied by increased proliferation and morphological 
changes. Pro-oncogenic processes are triggered by intrinsic (e.g. genetic alterations) 
and environmental factors (e.g. chronic UVR exposure) (Bandarchi et al, 2013) 
(Bermudez, 2014). The presence of a singular risk factor is not generally sufficient to 
induce melanoma development. Mutated BRAF (BRAFV600E) expression in melanocytes 
is associated with limited cell proliferation, resulting in the formation of benign 
neoplasms (melanocytic nevi), while additional genetic alterations are required for 
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melanoma initiation (Abildgaard & Guldberg, 2015) (Shtivelman et al, 2014). Most of 
cutaneous melanomas are classified as de novo, meaning that they are not associated 
with pre-existing nevus lesions (Greene et al, 1985). Melanoma cells are characterized 
by uncontrolled proliferation and high genetic heterogeneity. Depending on tumor 
localization and cell behaviour, it’s possible to distinguish between melanoma in situ, 
which is the earliest cancer stage where tumor cells are all confined to the epidermis, 
showing slow progression and better prognosis outcome (Mocellin & Nitti, 2011), and 
invasive melanoma. In this latter condition, melanoma cells show a widespread 
distribution within the dermis and closer interactions with the surrounding 
microenvironment composed of stromal cells (fibroblasts, endothelial cells, infiltrating 
inflammatory cells) and macromolecules (extracellular matrix and soluble factors). 
Microenvironment components together with the accumulation of genetic aberrations 
shape the tumor phenotype towards a more aggressive and invasive one (Villanueva & 
Herlyn, 2008). During melanoma tumor growth, melanoma cells undergo reversible 
alterations defined as phenotype-switching, characterized by a loss of cell proliferative 
potential and acquisition of prominent pro-invasive and pro-metastatic properties, 
making the tumor more prone to metastasize (Hoek et al, 2008) (Hoek & Goding, 2010). 
Formation of melanoma metastases is observed when cells leave the primary tumor and 
reach local and distant regions. The metastatic process is articulated in distinct stages. 
During stage I/II, melanoma cells start disseminating from the primary tumor and 
circulating via the vascular and lymphatic system. However, no metastases can be 
detected at these stages. Stage III is defined by the observation of clear lymph node 
metastases. Lymph nodes, and the sentinel lymph nodes in particular, are the primary 
sites where melanoma metastases form (Wong et al, 2018). In the most advanced 
melanoma phase (stage IV), cells colonize distant sites and re-acquire proliferative 
capacity. Melanoma metastases are especially found in lungs, bones, brain and liver 
(Tas, 2012) (Figure 1).  
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Figure 1: Schematic model of melanoma initiation and progression.In normal skin, melanocytes are 
located in the basal layer of the epidermis. Melanocytes produce melanin which is then transferred to the 
surrounding keratinocytes. Combination of genetic alterations and exposure to carcinogenic stimuli (e.g. 
UVR) determine the malignant transformation of melanocytes to melanoma cells. The accumulation of 
genetic mutations and the activation of oncogenic signaling pathways result in a more aggressive 
phenotype of melanoma cells («phenotype switching»), which are now capable to invade the dermis, 
forming the «pre-metastatic niche», and to interact with the stromal components (invasive melanoma). 
Chromosomal aberrations and stimulation from the tumor microenvironment are crucial for the metastatic 
process, where tumor cells leave the primary site and colonize, through extravasation in blood and 
lymphatic vessels, distant organs and tissues (metastatic melanoma). 
1.1.3 Key signalling pathways and oncogenes in melanoma 
Melanoma development and progression are defined by the deregulation of molecular 
and cellular mechanisms. In particular, the activation of signal transduction pathways 
related to cell proliferation and survival, together with repression of tumor suppressors, 
greatly contribute to the oncogenic potential of melanoma cells. 
Several signalling pathways have been characterized in detail in relation to melanoma 
progression, including the mitogen-activated protein kinase (MAPK) pathway, which 
represents the most recurrently deregulated signalling cascade, the phosphoinositide 3-
kinase (PI3K) pathway, the MITF pathway and WNT/β-catenin pathway. For each of 
these processes, oncogenic driver mutations occur in key signalling factors. 
MAPK pathway 
Activation of MAPK signalling promotes biological processes like cell proliferation, cell 
survival, differentiation and apoptosis (2015; Obenauf et al, 2015). Cells expose tyrosine 
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kinase- and cytokine-receptors on their surface, which, when stimulated, communicate 
the signal to monomeric GTPases belonging to the RAS protein family. RAS activates a 
serine/threonine kinase cascade, composed of BRAF, MAP2K (MEK) and MAPK (ERK). 
Active ERK phosphorylates a wide range of substrates, including transcription factors, in 
this way mediating cell growth and survival effects. In melanoma, the MAPK signalling 
pathway is mostly found constitutively activated. In almost 50% of melanoma patients, 
this is due to BRAF gene mutations. The most frequent oncogenic BRAF mutation (90% 
of BRAF mutation cases) is an amino acid substitution (the valine at position 600 is 
replaced by a glutamic acid; V600E). As a result, the BRAFV600E variant encodes for a 
constitutively active BRAF protein (Ascierto et al, 2012). Almost 20% of melanoma 
patients are characterized by activating mutations of the neuroblastoma RAS (NRAS) 
protein, which is the predominant RAS isoform expressed in melanoma. Q61R and 
Q61K amino acid substitutions are the most frequent NRAS mutations. NRAS-mutated 
melanomas are associated with an aggressive phenotype and a worse prognosis 
compared with non-NRAS mutated melanomas (Jakob et al, 2012) (Lee et al, 2011).  
 
PI3K pathway 
Besides MAPK pathway activation, NRAS induces also PI3K signalling. Activated PI3K 
promotes the phosphorylation of phosphatidylinositol-3, 4, 5-triphosphate (PIP3), 
required for the recruitment and activation of the protein kinase B (AKT), a 
serine/threonine kinase involved in the control of cell survival, motility, angiogenesis and 
metabolism. PIP3 is negatively regulated by the tumor suppressor PTEN. Loss of PTEN 
by gene deletion or by epigenetic interference is highly recurrent in melanomas with the 
worst clinical outcome (Aguissa-Toure & Li, 2012) (Mirmohammadsadegh et al, 2006). 
 
MITF pathway 
Melanocytes normally expose the melanocortin 1 receptor (MC1R) on their surface, 
which is usually stimulated by the α-melanocyte-stimulating hormone (α-MSH). MC1R 
activation leads to an increase of microphthalmia-associated transcription factor (MITF) 
expression. MITF plays a crucial role in melanocyte survival and differentiation by 
regulating the genes responsible for melanin synthesis, including tyrosinase (TYR), 
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tyrosinase-related protein 1 (TYRP1), tyrosinase-related protein 2 (TRP2, DCT), Melan-
A (MART1) and melanosomal matrix protein 17 (PMEL17) (Goding, 2000) (Du et al, 
2003). The role of MITF in melanoma is controversial. The MITF gene has been found to 
be amplified in about 20% of the melanomas and its expression is associated with 
reduced patient-survival. On the other hand, several studies showed that MITF 
expression and regulatory activity is impaired in melanoma cells (Wellbrock & 
Arozarena, 2015). 
 
Wnt/β-catenin pathway 
Wnt proteins are involved in pathogenic mechanisms in various cancer types (Zhan et 
al, 2017). In WNT/β-catenin signalling (also known as the canonical pathway), the WNT 
ligand binds to Frizzled (Fz) receptors and induces accumulation of β-catenin in the cell. 
β-catenin enhances the transcription of Wnt target genes that are described as inducers 
of tumor growth and mediators of drug resistance (Sinnberg et al, 2011). 
 
c-KIT 
The oncogene c-KIT (CD177) encodes for a tyrosine kinase receptor expressed on the 
surface of stem-like tumor cells (Galli et al, 1993). c-KIT mutations are detected in about 
1% of all melanomas and mostly observed in non-sun exposed lesions (acral /mucosal 
melanoma). Mutated c-KIT constitutively stimulates the MAPK and PI3K pathways via 
RAS activation (Ashida et al, 2009) (Carlino et al, 2014). 
 
CDKN2A 
The cyclin-dependent kinase Inhibitor 2A (CDKN2A) is a cell-cycle regulator. The 
CDKN2A gene encodes two different transcript variants, which both function as tumor 
suppressor proteins. p16INK4A is involved in the regulation of retinoblastoma (RB) 
signalling related to cell cycle checkpoint control, while p14ARF plays a role in p53-
mediated apoptosis. CDKN2A mutations abrogate these tumor suppressor mechanisms 
(Freedberg et al, 2008). CDKN2A is frequently mutated in cases of familial melanoma 
(Goldstein, 2004).  
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NF1 
The tumor suppressor neurofibromatosis 1 (NF1) is expressed in many cell types. It 
inhibits RAS activity. NF1 mutations impair its tumor suppressor activity and are 
frequently detected in melanoma lesions on chronically sun-exposed skin (Kiuru & 
Busam, 2017).  
 
1.1.4 Melanoma treatment options 
Malignant melanoma is characterized by high complexity and genetic heterogeneity. For 
this reason, a great number of therapeutic approaches has been developed in the past 
decades, clinically tested and approved by the US Food and Drug Administration (FDA), 
with the aim to treat and cure melanoma. Depending on tumor histopathological 
parameters, the presence of metastases and the genetic profile of a melanoma, the 
most suitable therapeutic options are chosen among: surgical resection, chemotherapy, 
radiotherapy, immunotherapy and targeted therapy. 
Surgical treatment 
For patients in the earliest stages of melanoma disease before the occurrence of 
metastases, surgical excision of the tumor mass represents the principal therapeutic 
option. The overall survival rate after surgical resection is 92% (Torre et al, 2015). 
However, the presence of unresectable tumors and disseminated metastases required 
the development of alternative and effective treatment options.  
 
Chemotherapy 
The use of chemotherapeutic agents is a standard approach for the treatment of cancer. 
However, chemotherapeutic treatment of melanoma patients does not really increase 
their overall survival (OS). For this reason, chemotherapeutic drugs (dacarbazine, 
temozolomide) are mainly used for palliative treatment of patients with advanced 
melanoma (Wilson & Schuchter, 2016). 
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Radiotherapy 
For many cancer types, radiation therapy is solely applied as a complement to surgical 
treatment or alternatively as a palliative cure in late-stage melanoma associated with 
painful conditions (i.e. unresectable brain metastases) (Mahadevan et al, 2015). 
 
Immunotherapy 
Innovative therapeutic approaches developed in the last few years focused on the 
interactions between tumor cells and the immune system. In particular, efforts have 
been made to stimulate and enhance the mechanisms by which cytotoxic T cells, which 
play a central role in pathogen-specific immune response, undergo activation and clonal 
amplification once tumor cells expose specific antigens on their surface. As a 
consequence, activated T cells specifically kill tumor cells (Lanitis et al, 2017). It has 
been shown that during tumor progression and metastases formation, various 
immunosuppressive mechanisms are activated. Current immunotherapy strategies aim 
at circumventing the immunosuppressive effects and inducing a prompt and effective 
immune response. First FDA-approved immunotherapies for melanoma were based on 
the use of cytokines (Interferon α-2b, FDA-approved in 1995; interleukin 2, approved in 
1998; peginterferon α-2b, approved in 2011) (ClinicalTrials.gov). These cytokines 
mediate immunomodulative and antitumor effects via stimulating the activation of 
immune cells (Rafique et al, 2015) (Kirkwood et al, 2001) (Eggermont et al, 2008) (Krieg 
et al, 2010). Despite the poor patient response, cytokine-based immunotherapies are 
still used in combinatorial treatment studies. Different immunotherapy-based approaches 
were developed to specifically interfere with immunosuppressive mechanisms. One of 
the most promising and widely used immunotherapeutic agent, ipilimumab (anti- CTLA-4 
antibody), efficiently reverses the drug tolerance induced by the cytotoxic T lymphocyte-
associated antigen 4 (CTLA-4). Ipilimumab treatment, approved by the FDA in 2011, 
reverses CTLA-4-mediated T cell dormancy (Grosso & Jure-Kunkel, 2013). Melanoma 
patients treated with ipilimumab showed promising drug responses, although 
accompanied by modest to severe adverse effects (AEs) (Hodi et al, 2010) (Wolchok et 
al, 2010). A new immunotherapy strategy was developed to prohibit immunosuppressive 
effects resulting from the binding of the programmed cell death protein 1 (PD-1) 
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receptor, present on the surface of T cells, with the PD-1 ligand (PD-L1), exposed by 
several cancer cell types. The PD-1/PD-L1 interaction promotes T cell suppression. Anti-
PD-L1 antibodies (nivolumab, FDA-approved in 2014; pembrolizumab, approved in 
2015) represent a valid immunotherapeutical option to reverse tumor-mediated T cell 
suppression and to positively modulate immune response, with relatively modest AEs 
(Tsai et al, 2014) (Jazirehi et al, 2016). Additional immunotherapy options include the 
development of vaccines (g100 peptide, Toll like receptor agonists) (Yuan et al, 2009a) 
(Kanzler et al, 2007), the use of oncolytic viruses or the administration of melanoma-
specific mature T cells (Pol et al, 2016) (Dudley et al, 2008).  
 
Targeted therapy 
The identification of activating mutations driving melanoma progression permitted to 
develop new therapeutic strategies, based on small molecules able to specifically target 
and inhibit the mutated protein variants. BRAFV600E , the most common mutation in 
melanoma and responsible for aberrant MAPK pathway activation, is effectively inhibited 
by vemurafenib (PLX4032, FDA-approved in 2011) and dabrafenib (approved in 2013). 
Selective BRAF inhibition resulted in remarkable clinical responses, namely a strong 
tumor regression in melanoma patients harbouring the BRAF mutation. Trametinib, the 
inhibitor of MEK (approved in 2013), also achieves beneficial effects in terms of patient 
response and overall survival rates. Alternative molecular targets for drug inhibition 
include the tyrosine kinase receptor c-KIT (imatinib) and the PI3K-AKT pathway (PI-103; 
rapamycin) (Livingstone et al, 2014) (Li et al, 2013). An increasing number of novel 
targets has been included in clinical trials in order to further optimize targeted therapy 
approaches and to face the huge molecular complexity observed in melanoma. FDA-
approved therapies are currently used for treating unresectable advanced melanoma, as 
monotherapy or in combinatorial treatments (Gazze, 2018). Despite the promising 
beneficial effects of targeted therapy observed in patients with malignant melanoma, 
dramatic tumor relapses occur in most of the cases, together with an acquired 
resistance to the previously used drug (Kalal et al, 2017). Several mechanisms may 
contribute to the development of resistance: i) the presence and/or accumulation of 
additional genetic aberrations affecting components of the MAPK and PI3K signalling 
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pathways, such as NRAS mutation, aberrant splicing variants of BRAF or loss of NF1 or 
PTEN tumor suppressors; ii) alterations in cellular processes, like cell cycle control or 
apoptotic program; iii) cellular effects mediated by the close interactions with tumor 
microenvironment components; iv) high degree of intra-tumor heterogeneity. Novel 
targeted strategies aim at overcoming resistance via the identifying novel oncogenic 
drivers of melanoma and by the use of combinatorial treatments. 
 
1.2 Epigenetics in melanoma  
 
1.2.1 Epigenetics overview 
The term “epigenetics” was first used by Conrad Waddington in 1942 to indicate the 
influence of the interactions between genes and microenvironment during development 
and embryogenesis (Noble, 2015). Improved knowledge of molecular mechanisms 
allowed to identify peculiar phenotypic traits which are induced or repressed by 
alterations of the chromatin structure. Interestingly, chromatin changes were not found 
as related to modification of DNA sequence, but attributed to reversible, dynamic and 
heritable variations occurring on chromatin structure components.  
Chromatin is a macromolecule composed of genomic DNA, RNA and proteins. The 
basic chromatin unit is the nucleosome, which is constituted of 147 base pairs (bp) of 
DNA assembled with an octamer core of alkaline proteins, known as histones (H3, H4, 
H2A, H2B) (McGinty & Tan, 2015). The C- and N- terminal amino acid chains (tails) of 
histones are subjected to a wide range of posttranslational modifications (PTMs). 
Histone modifications induce drastic changes of the structural conformation of 
chromatin, which are directly linked with the alteration of molecular mechanisms: 
depending on the local level of chromatin compaction (high-condensed form, termed 
heterochromatin; low-condensed form, referred to as euchromatin), genomic sites may 
be more or less accessible for the gene regulatory machinery. 
Transition from heterochromatin to euchromatin (and vice versa) is strictly modulated by 
DNA methylation and histone modifications. DNA methylation is the addition of 
hydrophobic methyl groups (chemical formula: -CH3) to specific genomic DNA bases 
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(cytosine) located at important regulatory sites defined as CpG islands. DNA methylation 
prevents these regions from binding transcription factors (TFs), resulting in the 
repression of the corresponding gene (Newell-Price et al, 2000). Epigenetic changes are 
regulated by various enzymes that, depending on their specific functions, can be defined 
as: i) “writers”, responsible for the insertion of chemical structures (epigenetic marks) to 
histones and DNA; ii) “readers”, enzymes capable of recognizing and interacting with 
epigenetic traits; iii) “erasers” enzymes mediating the removal of epigenetic 
marks(Gillette & Hill, 2015) (Figure 2).  
 
 
Figure 2: Landscape of epigenetic mechanisms.Human chromosomes are physically organized in 
complex of DNA, RNA and protein which form the chromatin. Chromatin is in turn composed by 
nucleosomes, in which DNA segments are wrapped around octamers of histone proteins. Chromatin 
structure can undergo reversible modifications which lead to alterations in gene expression. Epigenetic 
changes comprise the methylation of specific DNA nucleotides (DNA methylation) and chemical 
alterations of amino acid residues protruded from the N terminal tails of histones (histone modifications). 
Each histone exhibits a wide range of histone modifications which generally impact on the chromatin 
condensation state and, therefore, on the gene expression. Based on this, histone marks can be 
categorized as repressive (mostly found in the highly condensed chromatin state, heterochromatin) or as 
activating (enriched in the euchromatin, which is less compacted). Epigenetics marks mediate 
transcriptional effects also by recruiting trans-regulatory factors. 
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1.2.2 Histone modifications 
PTMs of histones have been reported to greatly contribute to regulatory mechanisms by 
directly inducing structural changes in the chromatin structure or by recruiting 
transcription factors and other trans-elements (Bannister & Kouzarides, 2011). Each 
histone protein possesses a great number of modification sites, mostly located at the 
terminal tails. Multiple histone modifications can co-occur on the same histone. Although 
several histone marks are generally associated either with enhancing (H3Ac, H3K4, 
H3K36, H3K9me1) or repressing (H3K9me2/me3, H3K27) transcription (Dong & Weng, 
2013), the final impact of histone modifications on gene expression is defined by multiple 
variables, like the histone type and amino acid residues involved in PTMs, as well as the 
interplay with other histone marks in the surrounding area (“histone cross-talk”). The 
highly complex scenario of the interactions and combinatorial effects of PTMs is also 
called histone code (Lee et al, 2010). Gene regulation-related histone modifications can 
be generally classified as: acetylation, methylation, phosphorylation and ubiquitination 
(Figure 3). Other PTMs (sumoylation, citrullination, glycosylation, carbonylation, ADP-
ribosylation, formation of histone variants) are much less frequent.  
 
Figure 3: Overview of histone modifications.Histone proteins exhibit side chains subjected to specific 
post-translational modifications. Lysine (K) residues can be acetylated, methylated and ubiquitinated. 
Arginine (R) is mostly found acetylated, while histone phosphorylation occurs on serine (S) and threonine 
(T) residues. Histone modifications are modulated by different classes of enzymes responsible for the 
adding («writers»), removal («erasers») or recognition («readers») oh histone PTMs. 
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Histone acetylation 
Acetylated histones carry functional acetyl groups (chemical formula: -CO-CH3) at their 
N-terminal tails. Depending on the histone type, acetylation is restricted to specific lysine 
(Lys) residues. The introduction and removal of an acetyl group are mediated by histone 
acetyl transferases (HATs) and histone deacetylases (HDACs), respectively. Several 
HAT/HDAC variants have been identified which can be distinguished by their structural 
conformations and by cell type distribution. HAT-mediated histone acetylation induces 
critical molecular effects. First, introduction of acetyl groups mediated by the CREB-
binding protein (CBP) destabilizes the histone-DNA interactions, rendering the chromatin 
more accessible for TFs (Verdone et al, 2005). Moreover, histone acetylation marks are 
recognized and bound by bromodomain-containing proteins. Several factors contain 
multiple bromodomains, which increases the complexity of histone acetylation-related 
regulatory effects (Josling et al, 2012). 
 
Histone methylation 
Histone methylation is the addition of methyl groups to specific basic residues (lysine, 
arginine) protruding from the terminal tails. In contrast to acetylation, a particular amino 
acid residue can incorporate one (monomethylation), two (dimethylation) or three 
(trimethylation) methyl groups (Greer & Shi, 2012). Histone methyltransferases (HMTs) 
represent the key writer enzymes for this histone mark. Each HMT shows methylation 
site-specificity: in particular, the EZH2 enzyme specifically methylates Lys 27 of histone 
H3 (H3K27), resulting in gene silencing (Yoo & Hennighausen, 2012). MLL1 catalyses 
the methylation of H3K4, mostly associated with gene activation (Guenther et al, 2005), 
while SUV39H and members of the SET-domain protein family, like SETDB1 and G9a, 
regulate the H3K9 methylation status, often linked with transcriptional repression 
(Stewart et al, 2005). Histone demethylases (HDMs) act as eraser factors, removing 
methyl groups from histone residues. Lysine-specific demethylase 1 (LSD1) is the most 
well characterized histone demethylase (Chen et al, 2012). Methylation tags are 
specifically recognized by proteins containing chromodomains, Tudor domains or MBT 
domains (Yap & Zhou, 2011). Functional effects induced by histone methylation are very 
complex and depend on the localization of the histone tag, number of added methyl 
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groups (mono- , di-, trimethylated status) and, finally, concomitant epigenetic marks for 
that particular genomic region.  
 
Histone phosphorylation 
Histone proteins contain various serine and threonine residues which can be 
phosphorylated under physiological and pathological conditions. Histone 
phosphorylation and dephosphorylation mechanisms are mediated by histone-specific 
enzymes, such as H2BS32ph, RSK2 and MSK1/2 kinases, and by less specific 
components of signalling cascades, like ERK and protein phosphatases (PP) 1 and 2 
(Rossetto et al, 2012). Of note, it has been shown that histone phosphorylation marks 
together with histone acetylation marks synergistically contribute to gene regulation 
(Cheung et al, 2000). 
 
Histone ubiquitination 
The functional role of histone ubiquitination is still subject of debate. Ubiquitination is 
predominantly observed at lysine residues of histone H2A and H2B. In the first case, the 
histone mark is associated with gene activation, while monoubiquitinated H2B is mostly 
found in silenced gene regions. Ring finger proteins RING1A/B, BMI1, BARD1, RNF20 
and RNF40 strongly enhance E3 ubiquitin ligase activity towards histone proteins. 
Deubiquitinating factors, in particular ubiquitin-specific proteases (USPs), revert this 
catalytic reaction (Cao & Yan, 2012).  
 
1.2.3 Histone modifications in cancer and therapeutic options 
During malignant transformations, a wide range of oncogenic driver mutations affects 
epigenetic regulators, leading to alterations of chromatin structure and histone 
modification pattern. Epigenetic aberrations, in turn, drastically change gene regulatory 
mechanisms leading to an increase of oncogene expression, or tumor suppressor gene 
silencing. For all these reasons, epigenetic alterations strongly contribute to tumor 
development and progression. Moreover, the global landscape of epigenetic changes, 
especially of histone modifications, may represent a valuable predictive indicator of 
clinical outcome in cancer. The identification of the main dysregulated epigenetic 
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components in the last few years allowed to develop epigenetic targeted therapies and 
to test them against various solid cancers. Histone acetylation and methylation are the 
most deregulated epigenetic pathways in cancer (Muntean & Hess, 2009). Histone 
acetylation patterns are defined by the activity of HAT and HDAC enzymes. The histone 
acetylase CBP has been found mutated or aberrantly expressed in solid tumors and 
leukemias (Gao et al, 2014) (Giotopoulos et al, 2016). In the same way, HDACs are 
highly expressed in cancer and participate in tumorigenic mechanisms (Yang et al, 
2014). To counteract HDAC activity in malignancies, unselective and selective HDAC 
inhibitors (HDACi) are currently used as therapeutic options. It has been reported that 
HDACi, such as vorinostat (unselective) and romidepsin (selective for HDAC1/2 
inhibition), induce tumor cell cycle arrest and are included in clinical trials on cutaneous 
and peripheral T cell lymphomas (Olsen et al, 2007) (Piekarz et al, 2011). Epigenetic 
regulators related to histone methylation and frequently deregulated in cancer belong to 
both the HMT and HDM family. EZH2 is overexpressed in breast and prostate cancer 
(Pourakbar et al, 2017) (Melling et al, 2015). In contrast, various hematopoietic 
malignancies exhibit inactivating mutations of EZH2 (Herviou et al, 2016), suggesting 
that the role of EZH2 in cancer is cell context- and mutation-dependent. EZH2 inhibition 
approaches rely on competitive binding using analogues of the EZH2 cofactor, S-
adenosyl methionine (SAM). DZNep, EI1 and GSK126 specifically target EZH2-positive 
tumor cells, inducing growth arrest and apoptosis (Kim & Roberts, 2016). The H3K9 
HMTs G9a and SUV39H are targeted by the small molecule inhibitors BIX01294 and 
chaetocin, respectively (Chiba et al, 2015) (Chang et al, 2009). The histone demethylase 
LSD1 plays a crucial role in acute myeloid leukemia (AML). Tranylcypromine (TCP) was 
indicated to effectively target LSD1 in tumor cells (Sun et al, 2016).  
Besides epigenetic writers and erasers, reader enzymes are also important for the 
regulation of molecular mechanisms in normal or tumor-related conditions. Approaches 
utilizing small molecule inhibitors against bromodomain proteins belonging to the BET 
family or chromodomain HP1 represent innovative and promising therapeutic options for 
the treatment of cancer (Yu et al, 2015) (Castonguay et al, 2015). 
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1.2.4 Histone modifications in malignant melanoma 
Recently, novel molecular mechanisms linked with melanoma have been described, 
further implementing the complex landscape of melanoma pathogenesis. In addition to 
genetic abnormalities and cell signalling dysregulations, several epigenetic alterations 
have been identified and characterized. Melanomas have one of the highest mutation 
rates among solid tumors (Hodis et al, 2012), and several of these mutations affecting 
epigenetic factors. Recent studies indicate how changes in the expression and/or activity 
of epigenetic regulators lead to critical consequences in melanoma progression, and that 
approaches that selectively target epigenetic factors represent an innovative and 
promising therapeutic strategy for the treatment of melanomas. Regulation of 
melanoma-related factors like the SRY-Box 10 (SOX10) and the signal transducer and 
activator of transcription 3 (STAT3) proteins is directly modulated by histone H3K27Ac 
levels and by HDAC6 inhibition, respectively (Verfaillie et al, 2015) (Lienlafa et al, 2016). 
Moreover, HDACi treatment impairs the activation of the MAPK pathway (Hornig et al, 
2016). In contrast to these anti-tumorigenic effects, a recent work showed that 
melanoma cells exposed to HDACi possess a more aggressive and invasive phenotype 
(Diaz-Nunez et al, 2016). The EZH2 protein is overexpressed in metastatic melanoma. 
In primary melanomas, EZH2 expression correlates with the expression of BRAFV600E 
and with melanoma proliferation (Yu et al, 2017). Functionally, EZH2 induces alterations 
of genome-wide H3K27me3 enrichment and distribution. H3K27me3 modulates 
CDKN2A oncogenic splicing mechanisms (Souroullas et al, 2016). The EZH2 inhibitor 
GSK126 impairs melanoma cell invasiveness (Tiffen et al, 2015). The histone 
demethylases LSD1 and JMJD2C induce oncogenic transformation of senescent 
melanocytes by reducing H3K9me3 marks. Loss of H3K9me3 promotes E2F target gene 
expression, resulting in melanocytes overcoming the cell cycle block. Treatment with 
LSD1 inhibitors reverts tumorigenic transformation and restores senescence (Yu et al, 
2018). The epigenetic reader protein BRD4, which belongs to the BET family, is 
overexpressed in melanoma. BRD4 inhibition leads to reduced cell proliferation rates 
(Segura et al, 2013). 
Targeting therapies aiming at epigenetic factors are being included in clinical trials to 
treat melanoma and are especially used in combinatorial treatments. To date, the most 
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promising epigenetic-based therapeutic option is given by the combination of HDACi and 
TRAIL, able to stimulate tumor cell apoptosis (Jazirehi & Arle, 2013).  
Improved targeted therapies against epigenetic factors may serve as alternative 
therapeutic approach to overcome melanoma chemoresistance. Recently, it has been 
reported that treatment of MAPKi-resistant melanoma patients with the HDACi 
panobinostat and the HMTi decitobine in combination with chemotherapy yields 
encouraging responses in patients (Ibrahim et al, 2016) (Alcazar et al, 2012). In a 
different study, the histone deacetylase SIRT6 was shown to modulate melanoma 
chemosensitivity to MAPKi via the regulation of IGF-binding protein 2 (IGDFB2) (Ming et 
al, 2014) (Figure 4). 
 
 
Figure 4: Epigenetic mechanisms in melanoma.Melanoma cell malignant transformation is determined 
by the presence and accumulation of chromatin modifications. Several studies have reported that the 
development of melanoma-specific properties is triggered by epigenetic events and that, moreover, 
targeting epigenetic regulators might represent a promising therapeutic strategy for melanoma treatment. 
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1.3 SETDB1 
 
SETDB1 encodes for a protein of 1307 amino acids termed as SET-domain protein, 
bifurcated 1 (SETDB1; ESET; KMT1E), belonging to the SET-domain containing protein 
superfamily. 
 
1.3.1 SET-domain protein superfamily 
The SET (acronym of Su(var)3-9, Enhancer-of-zeste and Trithorax) domain is a protein 
structure of 130 amino acids initially identified in several Drosophila species (Tschiersch 
et al, 1994). A large number of human proteins are characterized by the presence of an 
active SET domain, such as members of the SUV39 family (SUV39H, G9a, SETDB1 
and SETDB2), SET 1 family (MLL1, MLL2, MLL4), SET 2 family (NSD2, NSD3), RIZ 
family (PRDM1, PRDM2), SMYD family (SMYD1, SMYD 3), EZ family (EZH1, EZH2), 
SUV 4-20 family (SUV 4-20H1, SUV 4-20H2) and SET7/9 and SET 8 proteins (Dillon et 
al, 2005). Almost all the identified SET-domain proteins function as lysine 
methyltransferases (KMTs). Crystallographic studies on SET-domain containing proteins 
showed that the SET domain is generally assembled in a well-conserved multi-motif 
structure located at the C-terminus, enclosed by the pre-SET and post-SET domains. 
The pre-SET domain is particularly rich in cysteine residues conjugated with zinc ions, 
required for protein scaffolding. The post-SET domain contains three conserved 
cysteines which play a crucial role during HMT activity by physically interacting with the 
terminal tails of the histone and by supporting the binding of the cofactor SAM. The 
specificity of a HMT for a particular histone is guaranteed by invariant residues present 
in SET domain sequence (Rea et al, 2000). 
 
1.3.2 SETDB1 gene mapping and expression 
The SETDB1 coding sequence is highly conserved among different species. The human 
SETDB1 gene is located on chromosome 1 (cytogenetic band: 1q21.3, plus-strand 
orientation) and comprises about 37 kilobases with 23 exons. Three different isoforms 
are known for SETDB1: the first transcript variant encodes for the full-length protein, 
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constituted of 1291 amino acids, while the other alterative splicing isoforms produce 
truncated forms of SETDB1. The SETDB1 promoter contains binding sites for TFs, such 
as GATA-1, NFY, ATF6, Cdc5, Lmo2 and Sp1. SETDB1 is ubiquitously expressed in 
human organs and tissue under normal conditions (Human Protein Atlas). 
 
1.3.3 SETDB1 protein structure and localization 
In addition to SET, pre-SET and post-SET domains, SETDB1 also possesses a methyl-
CpG-binding domain (MBD), involved in DNA binding and protein-protein interaction 
processes (Bird, 2001), and three tudor domains (Figure 5). Recently, it has been 
shown that tudor domains have the capacity to read and bind methylated and acetylated 
residues on histone tails, and in that way contribute to the epigenetic functionality of 
SETDB1 (Jurkowska et al, 2017). Despite SETDB1’s HMT and DNA-binding activities 
SETDB1 is thought to also have a function in the nucleus. Recent studies showed that 
SETDB1 is mostly enriched in the cytoplasm and that nucleo-cytoplasmatic shuttling 
may represent a relevant aspect of the role of SETDB1 in human cells (Tachibana et al, 
2015). In the nucleus, SETDB1 is often found embedded in promyelocytic leukemia 
nuclear bodies (PML-NBs), large nuclear structures involved in transcriptional regulation, 
control of genomic stability and response to DNA damage (Bernardi & Pandolfi, 2003). 
 
Figure 5: SETDB1 protein structure.SETDB1 protein is 1307 amino acids in length and is organized in 
multiple functional domains, including 3 tudor domains (TD) located at the N terminus, a central methyl-
CpG-binding domain (MBD), while the C terminus exhibits the pre-SET, SET and post-SET motifs.  
 
1.3.4 SETDB1 functions and interactions 
The main role of SETDB1 is to trimethylate histone H3 at lysine 9 (H3K9me3) (Schultz et 
al, 2002), an epigenetic mark generally associated with gene repression (Yang et al, 
2002). In the presence of SAM, SETDB1 targets the terminal tails of histones H3 present 
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in euchromatin regions and catalyses H3K9 trimethylation. SETDB1-mediated transition 
from euchromatin to heterochromatin occurs when the heterochromatin protein 1 alpha 
(HP1α) recognizes and binds the trimethylated K9 at histone H3 via its chromodomain. 
HP1α then recruits KRAB-associated protein-1 (KAP1; Trim28) which, in turn, interacts 
with the repressor factor KRAB (Sripathy et al, 2006). The SETDB1-HP1α-KAP1-KRAB 
axis is one of the established SETDB1-centered repressive mechanisms, which include 
interactions of SETDB1 with several proteins, such as HDAC1/2 in the presence of 
mSin3A/3B corepressors (Yang et al, 2003), MBD1 assembled with MCAF cofactor 
(Hammond et al, 2006), ATF7IP (Basavapathruni et al, 2016), Argonaute protein 2 
(AGO2) (Cho et al, 2014), DNMT3A (Li et al, 2006) and PML (Kang, 2015). SETDB1 
protein interactions sustain the catalytic activity and substrate specificity of SETDB1. 
Transcriptional silencing occurs via direct promoter binding or through the incorporation 
into transcriptional repressor complexes. 
SETDB1 is involved in various physiological processes during mammalian embryonic 
development. Several studies indicate an involvement of SETDB1 in X-chromosome 
inactivation (Minkovsky et al, 2014). Oscillatory SETDB1 gene expression is observed 
during the early developmental stages of mouse embryos (Cho et al, 2012). Moreover, 
SETDB1 controls the expression of mesendoderm and ectoderm lineage-specific genes 
in mouse embryonic stem cells (Yuan et al, 2009b). 
 
1.3.5 SETDB1 in cancer  
SETDB1 plays an oncogenic role in a wide range of malignancies, in which it is 
aberrantly expressed and/or mutated (Figure 6). 
In breast cancer, SETDB1 is recurrently amplified and overexpressed. Mechanistically, 
Regina et al. observed that SETDB1 binds delta Np63 (ΔNp63), an oncogenic isoform of 
p63. SETDB1 sustains ΔNp63 activity during breast tumorigenesis (Regina et al, 2016). 
Another study showed that SETDB1 expression in mouse xenograft models is impaired 
by miR-7, inducing tumor regression and anti-metastatic effects (Fang et al, 2012). High 
levels of SETDB1 were also detected in colorectal cancer (CRC) cell lines a large group 
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of tissue samples derived from patients with CRC, correlating with the worst clinical 
outcome. SETDB1 dysregulation impacts the proliferation rate of CRC cells and thereby 
the tumor growth. Moreover, SETDB1 expression co-occurs with transcriptional silencing 
of p53 at the promoter level (Olcina et al, 2016); a similar SETDB1-mediated regulatory 
mechanisms affecting the expression of TP53 was also shown in liver (Fei et al, 2015) 
and non-small cell lung (NSCL) (Sun et al, 2015) cancer cells, resulting in enhanced 
tumor growth. In NSCL cells, SETDB1 stimulates the WNT/β-catenin signalling pathway 
(Sun et al, 2015). A promoting effect of SETDB1 on the invasive potential is observed in 
prostate (Saraon et al, 2013), as well as in lung cancer, where the SETDB1 gene is 
amplified (Rodriguez-Paredes et al, 2014). In contrast to these findings, recent works 
indicate anti-metastatic roles for SETDB1 in lung cancer. Functionally, SETDB1 inhibits 
the expression of ANXA2 (via TGFβ-SMAD2/3 signalling) (Wu et al, 2014) and FosB 
(mediated by ERK2 activation) (Na et al, 2016) factors involved in metastasis formation 
and cell survival, respectively. SETDB1 inhibits interferon γ response-mediated 
apoptosis in AML cells by blocking the transcription of endogenous retroviruses (ERVs) 
(Cuellar et al, 2017).  
The role of SETDB1 in melanoma has been studied by Ceol et al. in a zebrafish 
melanoma model, who observed a recurrent amplification of the 1q21 genomic region, 
corresponding to the SETDB1 locus. Additional SETDB1 copies correlate to SETDB1 
expression and enhance tumor growth and aggressiveness in zebrafish, especially if the 
BRAFV600E mutation is also present (Ceol et al, 2011). At the transcriptomic level, 
SETDB1 overexpression induces the repression of Hox genes that are involved in 
developmental processes (Taniguchi, 2014). The critical role of SETDB1 in melanoma 
was further confirmed in a more recent study showing high levels of SETDB1 in patients 
with metastatic melanoma (Miura et al, 2014). On the other hand, Shi et al. observed 
that SETDB1-silencing impairs the invasiveness and metastatic potential of human 
melanoma cells in vivo (Shi et al, 2017).  
In our laboratory, the contribution of SETDB1 to melanoma pathogenesis was further 
elucidated. The SETDB1 gene was found highly amplified and overexpressed in tissue 
samples from primary melanomas and melanoma metastases. The deregulation of 
 
34 
 
SETDB1 expression in melanoma cell lines had drastic effects on melanoma 
proliferation, migration, invasion and in vivo tumor growth. Pharmacological silencing of 
SETDB1 with the small molecule inhibitor CAS 935693-62-2 strongly impacted 
melanoma cell viability (unpublished data; (Orouji, 2016)).  
Although the current knowledge about SETDB1 strongly supports its role as an 
oncogene in several cancer types including melanoma, little is still known about the 
underlying mechanisms of action. 
 
Figure 6: SETDB1 involvement in cancer.A variegated group of cancer types is characterized by high 
SETDB1 amplification and expression levels. Based on these parameters, tumor cells show different 
properties: SETDB1 overexpression is generally associated with increased tumor proliferation, migration 
and invasion. 
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2 Aim of the thesis 
 
Different studies and previous work conducted in our laboratory highlighted the 
involvement of the histone methyltransferase SETDB1 in melanoma progression. This 
project intended to extensively characterize SETDB1 features and functions which 
determine its oncogenic potential. 
This study firstly aimed at gaining insights into the mechanisms by which SETDB1 
mediates its pro-tumorigenic effects. For this reason, transcriptomic, molecular and 
cellular alterations following SETDB1 gain or loss should be investigated. 
Secondly, in this study I wanted to examine the SETDB1-induced epigenetic alterations 
associated with malignant transformation of melanoma cells.  
Lastly, drug-response experiments were performed to investigate whether SETDB1 
inhibition might affect the viability of cancer cells and therefore representing a promising 
therapeutic approach. 
  
 
36 
 
3 Materials and Methods 
 
3.1 Materials 
 
3.1.1 Reagents and Kits 
Product Company Catalog No. 
Adhesive Clear qPCR seals Biozyme 600238 
Agarose NEEO Ultra 
Qualität  
Carl Roth 2267,4 
Alamar Blue® Invitrogen DAL1100 
Ampicillin Carl Roth HP62.1 
BioCoat™ Tumor Cell 
Invasion Systems 
Corning 354165 
BSA-Powder, Albumin 
Fraction V 
Carl Roth 8076.2 
Complete Mini Protease 
Inhibitor Cocktail 
Roche Diagnostics 4693159001 
DAPI Roche 10236276001 
DH5α Competent Cells Thermo Fisher Scientific 18265017 
EcoRI (10 U/L) Thermo Fisher Scientific ER0271 
EcoRV (10 U/µL) Thermo Fisher Scientific ER0301 
Endofree Plasmid Maxi Kit Qiagen 12362 
EZ-ChIP™ Merck Millipore 17-371 
Fluorescence Mounting 
Medium  
Dako S3023 
High Performance 
Chemiluminescence Film 
GE healthcare 28906836 
HumanHT-12 v4 
Expression BeadChip Kit 
Illumina BD-103-0204 
Immobilon PVDF 
membrane, 0.45μM 
Merck Millipore IPVH00010 
Luminata Forte Western 
HRP Substrate 
Merck Millipore WBLUF0500 
MicroAmp Optical 96well 
Plate qPCR 
Thermo Fisher Scientific N8010560 
microtube afa fiber snap-
cap 
Covaris 520045 
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Midori Green Advance Nippon Genetics mg-04 
NEB Next Ultra DNA 
Library kit  
New England Biolabs E7370S 
NEBNext® Multiplex Oligos 
for Illumina® (Index 
Primers Set 1) 
New England Biolabs E7335S 
NuPAGETM NovexTM 4-12% 
Bis-Tris Protein Gels 
Thermo Fisher Scientific NP0335BOX 
NuPAGE™ LDS Sample 
Buffer (4X) 
Thermo Fisher Scientific NP0008 
NuPAGE™ Reducing Agent 
(10X) 
Thermo Fisher Scientific NP0004 
O’GeneRuler 1 kb DNA 
Ladder 
Thermo Fisher Scientific SM1163 
O'GeneRuler 100bp DNA-
Ladder 
Thermo Fisher Scientific SM1143 
PageRuler Plus Prestained 
Protein Ladder 
Life Technologies 26619 
Paraformaldehyd Sigma Aldrich P6148-1KG 
Pierce BCA Protein Assay 
Kit 
Thermo Fisher Scientific 23225 
Platinum Taq Polymerase Thermo Fisher Scientific 10966034 
Proteome Profiler Human 
Angiogenesis Array Kit 
R&D Systems ARY007 
Qiaprep Spin Miniprep Kit Qiagen 27106 
RevertAid First strand 
cDNA Synthesis Kit 
Thermo Fisher Scientific K1622 
Rnase-Free Dnase Set Qiagen 79254 
RNeasy Plus Mini Kit Qiagen 74136 
Rotilabo®-syringe filters, 
0,22 µm 
Carl Roth KH54.1 
Rotilabo®-syringe filters, 
0,45 µm 
Carl Roth P667.1 
Skim milk powder Gerbu Biotechnik 16021000 
Sodium hydroxide Carl Roth 6771.1 
SYBR Green PCR Master 
Mix 
Applied Biosystems 4309155 
TEMED Carl Roth 2367,3 
TritonX-100 Carl Roth 3051,4 
Tween® 20 Applichem A13890500 
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Venor Gem Classic Myco 
PCR Kit 
Minerva Biolabs 11-1100 
XhoI (10 U/L) Thermo Fisher Scientific ER0691 
X-treme GENE® 9 DNA 
Transfection Reagent 
Roche Diagnostics 6365787001 
 
3.1.2 Reagents for cell culture 
Product Company Catalog No. 
2-Mercaptoethanol  Gibco®Life 
Technologies 
31350010 
Blasticidine Sigma Aldrich 15205 
Calcein AM Fluorescent Dye Corning 354217 
DMSO  Carl Roth A994.2 
Fetal Calf Serum (FCS) Biochrom S0115 
Non-essential amino acids Sigma-Aldrich M7145 
PBS Sigma-Aldrich D8537 
Penicillin/Streptomycin Sigma-Aldrich P4333 
Polybrene Infection / Transfection 
Reagent 
Sigma Aldrich TR-1003-G 
Puromycin Carl Roth 240,1 
Trypan blue solution Sigma-Aldrich 93595 
Trypsin -EDTA solution Sigma-Aldrich  T3924 
 
3.1.3 Human cell lines 
Cell Line  Source Cell type Mutation 
A375 ATCC Melanoma cell line BRAF V600E 
HT144 ATCC Melanoma cell line BRAF V600E 
SK Mel 28 ATCC Melanoma cell line BRAF V600E 
C32 ATCC Melanoma cell line BRAF V600E 
HEK293T ATCC embryonic kidney cells WT 
 
3.1.4 Antibodies 
Specificity Source Company Catalog 
No. 
SETDB1 Mouse Biorad VMA00243
KT 
THBS1  Mouse Thermo Fisher MA5-13398 
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Scientific 
DCT Mouse Santa Cruz 
Biotechnology 
sc-74439 
β-Actin Rabbit Cell signalling 5125S 
Anti-rabbit IgG, HRP-linked Goat Cell signalling 7074S 
H3K9me3 Rabbit Abcam ab8898 
α-actinin Mouse Santa Cruz sc-17829 
Goat Anti-Rabbit IgG H&L 
Alexa Fluor® 488 
rabbit Abcam ab150077 
H3K4me1 rabbit Abcam ab8895 
Anti-mouse IgG, HRP-linked  Horse Cell signalling 7076 
 
3.1.5 Inhibitor drugs 
Product Company Catalog No. 
Aphidicolin Sigma Aldrich A0781-1MG 
Mithramycin A Bio Trend 10-2085-5mg 
Trametinib (GSK1120212) Selleckchem S2673 
Vemurafenib (PLX4032)  Selleckchem S1267 
 
3.1.6 Plasmids 
Name Source 
non-targeting shRNA  Addgene #1864 
pCMV-dR8.91 (Packaging) Konrad Hochedlinger (Harvard, Bosten, 
USA) 
pCMV-VSV-G (Packaging) Addgene #8454 
pLEX980-empty vector derived from pLEX980-SETDB1  
pLEX980-SETDB1  obtained from Craig Ceol (Children's 
Hospital Boston, USA) 
pLEX-980-SETDB1 1224K 1226A  derived from pLEX980-SETDB1 by site-
mutagenesis 
SETDB1 shRNA TRCN0000147130 
THBS1 shRNA TRCN0000226403 
TRP2-pLenti  derived from Addgene #17448 
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3.1.7 Primers 
Amplification 
target 
Forward Sequence Reverse Sequence 
h18S_qPCR  GAGGATGAGGTGGAACGTGT TCTTCAGTCGCTCCAGGTCT 
hSETDB1_qPCR CATCCAGGGCAGTGACTAATT
G 
CGGAGCTTCTGGTCTTTTGG 
hTHBS1_qPCR  GCCATCCGCACTAACTACATT TCCGTTGTGATAGCATAGGG
G 
hDCT_qPCR  CCACAGTTCTGACGCTGACA ACAAGCAAGCAAAGCGGAAA 
hSCG2_qPCR  CCAGGTCACTGGGGAGTCTG
CT 
TGAGCATCAACAATGCCA 
hTYRP1_qPCR  AAACTTTGGAGAGGGAAAATC
T 
CACAGGCAATATCCATTGTT
G 
hAPOE_qPCR  GTTGCTGGTCACATTCCTGG GCAGGTAATCCCAAAAGCGA
C 
hALDOC_qPCR  GCCAAATTGGGGTGGAAAAC
A 
TTCACACGGTCATCAGCACT
G 
hIL6_qPCR  ACAACCACGGCCTTCCCTACT
T 
CACGATTTCCCAGAGAACAT
GTG 
hCCL2_qPCR  CCTTCATTCCCCAAGGGCTC GGTTTGCTTGTCCAGGTGGT 
hMMP3_qPCR  CGGTTCCGCCTGTCTCAAG CGCCAAAAGTGCCTGTCTT 
HC/KA-SETDB1 
mutagenesis 
GGCCGCTACCTCAACAAGAG
TTGCAGCCCCAAC 
TTGGGGCTGCAACTCTTGTT
GAGGTAGCGGCC 
hTHBS1 
promoter_ChIP 
qPCR  
GGAAGGGCTTTGTGTTTGA CCTATACGGTGGCAGGAAA
G 
hGAPDH 
promoter_ChIP 
qPCR  
TACTAGCGGTTTTACGGGCG- TCGAACAGGAGGAGCAGAG
AGCGA 
 
3.1.8 Solutions and Buffers 
Transfer buffer (pH 8.3)  
25mM Glycine  
190mM Tris 
20% SDS  
20% Methanol  
dH2O  
Running buffer (pH8.3) 
25mM Glycine  
190mM Tris 
0.1% SDS  
dH2O  
 
TBS 10X (pH 7.6)  
150mM NaCl  
50mM Tris  
dH2O 
Washing buffer (TBST) 
0.02% Tween® 20 
1X TBS 
Blocking buffer (milk) 
5% Skim milk powder 
1x TBS 
Blocking buffer (BSA) 
5% BSA  
1x TBS 
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RIPA buffer 
4M NaCl  
1% IGEPAL (Sigma-Aldrich) 
10% Sodim dehocycholate  
10% SDS 
1M Tris, pH 8  
dH2O 
 
TEB buffer 
0.5% Triton X 100 
2mM phenylmethylsulfonyl fluoride  
 0.02% Sodium Azide  
dH2O 
 
SOC Outgrowth Medium  
New England BioLabs (B9020S) 
LB Medium  
20g LB-Medium (Carl Roth, X964.2) 
1l H2O 
Cell freezing medium 
80% FCS 
20% DMSO 
 
 
 
3.1.9 Devices  
Product Company 
12 Well Multiwell Plates Grenier Bio-One 
2100 Bioanalyzer Instrument Agilent 
6 Well Multiwell Plates Grenier Bio-One 
8-well Culture Slide Falcon 
AB 7500 Real-Time PCR Machine Applied Biosytems 
CELLSTAR® Cell Culture Flasks Grenier Bio-One 
ChemiDoc™ Touch Imaging System  Bio-Rad 
Haemocytometry Neubauer 
Hi-Seq 2000 system Ilumina 
Leica DM LS light microscope Leica 
MicroAmp Optical 96well Plate qPCR Thermo Fisher Scientific 
Microplates 24-well Falcon 
Microplates 96-well Falcon 
Nanodrop Spectophotometer ND-1000 Peqlab Biotechnologie GmbH 
Nikon Eclipse Ti Fluorescence Microscope Nikon 
Nunc™ Cell Culture Cryogenic Tubes Thermo Fisher Scientific 
S220 focused ultrasonicator Covaris 
Tecan Infinite F200 PRO Tecan 
Veriti™ 96-Well Thermal Cycler Thermo Fisher Scientific 
 
 
 
42 
 
3.1.10 Software tools 
Software name Source 
7500 Software v2.0.5 Applied Biosystems 
Chipster  Chipster Open source 
DAVID tool https://david.ncifcrf.gov/  
Galaxy software https://usegalaxy.org  
GraphPad PRISM GraphPad software 
HLImage++  Western Vision 
Image J NIH  
Image Lab 6.0.1 Bio-Rad 
Ingenuity® Pathway Analysis (IPA®) QIAGEN Bioinformatics 
Integrative Gene Viewer  Broad Institute 
javaGSEA Broad Institute 
NDP. view 2 Hamamatsu Photonics 
NIS-Element  Nikon 
Primer-BLAST https://www.ncbi.nlm.nih.gov/tools/primer-
blast/ 
TScratch  CSElab 
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3.2 Methods 
 
3.2.1 Cell culture 
Human melanoma cells, normal human melanocytes (NHM) and dermal fibroblasts 
isolated from healthy patient’s foreskin were cultured in MEF medium, composed by 
Dulbecco's Modified Eagle medium (DMEM; Gibco, Life Technologies),10% heat-
inactivated FCS (Biochrom), 0.1 mM β-mercaptoethanol (Gibco, Life Technologies), 1% 
non-essential amino acids (NEAA; Sigma-Aldrich) and 1% penicillin/streptomycin 
(Sigma-Aldrich), and stably kept at 37°C and 5% C02 in a humidified incubator. 
Experiments were conducted when the cells reached subclonfluency (around 80% 
confluence). Briefly, cells were washed with PBS (Sigma-Aldrich) to remove dead cells 
and debris, followed by trypsinization with trypsin-EDTA solution (Sigma-Aldrich). Once 
dissociated, viable cells stained with trypan blue solution (Sigma-Aldrich) were counted 
with a hemocytometer counting chamber and subsequently seeded at defined densities, 
according to the planned experiments. For long term storage cells were frozen by 
suspending them in freezing medium and keeping them at -80°C or in liquid nitrogen. 
Once thawed, cell lines were sub-cultured at least once before every experiment to allow 
them to recover after the freeze-thaw cycle. Identity of melanoma cells used for this 
study was authenticated by cell line authentication test (Multiplexion). Cells were 
routinely tested for mycoplasma contamination with the Venor®GeM Classic 
Mycoplasma detection kit (Minerva Biolabs). 
 
3.2.2 RNA isolation  
Total RNA from cultured cells was isolated using RNeasy Mini Kit (Qiagen), following 
manufacturer's instructions. To avoid genomic DNA contaminations, RNA samples were 
incubated with RNase-Free DNase (Qiagen) for 15 min at RT. RNA concentration and 
quality were evaluated with a NanoDrop ND1000 spectrophotometer.  
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3.2.3 cDNA synthesis and quantitative PCR 
cDNA was generated by reverse transcription of 500 ng of total RNA using the Revert 
Aid First Strand cDNA synthesis kit (Thermo scientific) according to the manufacturer’s 
protocol. cDNA was then diluted 1:10 in nuclease-free water before quantitative PCR 
experiments. Gene expression was assessed by real time (quantitative) PCR reaction. 
Briefly, cDNA was mixed with SYBR Green Master Mix (Applied Biosystems, Life 
technologies) and with specific primers able to amplify a defined mRNA. Primers were 
designed using PrimerBlast or obtained from a Primer Bank database (Spandidos et al, 
2008); primer efficiency was calculated by amplification of the target from serial fold 
dilutions. The full list of used primers is provided in section 3.1.7. Each PCR reaction 
was run in triplicates on 7500 Real-Time PCR System device (Applied Biosystems, Life 
Technologies) and the results analysed following the delta-delta Ct value method. 18s 
ribosomal RNA expression was used as endogenous control for all the experiments. 
 
3.2.4 Microarray data analysis 
Whole genome expression profiles from cells were obtained by using BeadChip 
HumanHT-12 v4 technologies (Illumina). RNA quality control, labelling and probe 
hybridization for sequencing were performed by the Genomics and Proteomics Core 
Facility at DKFZ. Raw expression data for each cell type and/or condition was quartile 
normalized and, by comparing two groups (each of them composed by at least two 
biological replicates), a Bayes statistical test was applied to obtain a set of differentially 
expressed genes, based on their fold change (FC, expressed as log2 of expression 
values). In order to predict any correlation between transcriptomic profiles and 
phenotypic states, gene expression data were further analysed by using gene set 
enrichment analysis (GSEA) (Subramanian et al, 2005) and Ingenuity Pathway analysis 
(IPA) tools. 
 
3.2.5 Protein extraction and Western blot 
Whole-cell lysate from cultured cells was obtained as follow: first, harvested cells were 
washed once in PBS and then resuspended in 100 μl RIPA buffer and vigorously 
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vortexed. Cells were lysed on ice for 30 min and then centrifuged at 15000 rpm, 20 min 
4°C. Supernatant containing protein lysate was finally collected and stored at -20°C. In 
order to isolate histone proteins, cell pellets were washed twice with PBS and then lysed 
by adding TEB buffer. After 10 min incubation on ice, cells were centrifuged at 10000 
rpm 10’ 4°C and the supernatant was discarded. Pellet was again resuspended in TEB 
and centrifuged as above. Histone-enriched protein lysates were then precipitated by 
adding 0.2M HCl solution, followed by an overnight incubation at 4°C. Samples were 
centrifuged ad 10000 rpm at 4°C 10 min and supernatant collected, neutralized with 
1/10 2M NaOH and stored at -20 °C. All the lysates’ protein concentrations were 
assessed with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific), following the 
manufacturer’s instructions. Depending on the cell type and the predetermined 
immunoblotting, around 15-50 μg of whole cell lysates or 10-20 μg histones-enriched 
protein samples were loaded and run on NuPAGETM NovexTM 4-12% Bis-Tris Protein 
gels (Thermo Fisher Scientific). Proteins were then transferred onto PVDF membranes 
(Merck Millipore). Membranes were first incubated 1h at RT with a blocking solution to 
avoid any unspecific antibody-protein binding, and then probed with specific antibodies, 
diluted in the same blocking buffer, during the overnight incubation at 4°C on a shaker. 
The following day, membranes were washed three times in 1X TBST buffer to remove 
the excess of primary antibody and then incubated with HRP-conjugated secondary 
antibodies for 1h at 4°C. After three additional washing steps, membranes were shortly 
exposed to Luminata Forte western HRP substrate (Merck Millipore) before developing. 
Acquired images were then analysed by ImageJ software (NIH). The full list of primary 
and secondary antibodies used in this study is described in section 3.1.4. 
 
3.2.6 ELISA Proteome Profiler 
Cells were seeded and cultured until they reached around 80% confluence. Then, cell 
supernatant was collected and tested with the Proteome Profiler Human Angiogenesis 
array kit (R&D System), following the manufacturer’s instructions. Protein signals were 
quantified by HLImage++ image analysis software (Western Vision).  
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3.2.7 Mice xenografts 
In vivo experiments were conducted in the animal facility of German Cancer Research 
Center, in accordance with national guidelines and regulations. 1-2x106 melanoma cells 
were subcutaneously injected in NOD-SCID mice. Vital parameters of the mice and 
tumor growth were routinely monitored and mice were sacrificed once the tumor reached 
the size of 1,5 cm. Tumors were excised, fixed in 4% paraformaldehyde (PFA) and 
finally embedded in paraffin sections for further investigations. 
 
3.2.8 Immunohistochemistry and Tissue Microarray (TMA) 
Paraffin embedded tissues were stained with antibodies specific against SETDB1 and 
THBS1. Images were acquired with Nikon NIS Element software.  
Human tissue samples derived from healthy donors or patients with melanoma were 
assembled in TMA samples. TMA sample preparation was previously described 
(Wagner et al, 2015). Following immunostaining, TMAs were scanned by the NCT-
Gewebebank facility at the pathology unit, University of Heidelberg. Informed consent 
was obtained from each patient included in this study, which was performed in 
accordance to the ethical vote 2010-318N-MA (ethics committee II of Heidelberg 
University). 
 
3.2.9 Bacterial transformation and isolation of expression vectors  
pLEX980-SETDB1 vector was kindly provided by Dr. Craig Ceol. pLEX980-empty vector 
control was generated by cutting the SETDB1-coding sequence from pLEX980-
SETDB1. pLEX-980-SETDB1 1224K 1226A plasmid was produced by performing site-
directed mutagenesis. SETDB1 ORF was amplified with specific primers that introduced 
point mutations to the SETDB1 ORF. Mutated SETDB1 ORF was then introduced into 
pLEX980. SETDB1 and THBS1 gene knockdown was performed by using shRNA 
against SETDB1 (TRCN0000147130) and THBS1 (TRCN0000226403) (RNAi 
Consortium shRNA library, Broad Institute; Sigma-Aldrich), while a non-targeting shRNA 
(Addgene, No. 1864) was used as control. Constitutive GFP and constitutive TOMATO 
plasmids were used for 2D invasion assay. The TRP2-pLenti reporter construct used in 
 
47 
 
this study contains the ORF of GFP under the control of the DCT (TRP2) promoter. In 
order to obtain amplified plasmid DNA, competent E. coli bacteria were transformed. 
Briefly, competent bacterial cells (DH5α, Sigma-Aldrich) from E.coli were first thawed on 
ice and then mixed with up to 100 ng of plasmid DNA and incubated for 40 min on ice. 
Next, bacteria were subjected to heat-shock for 3 min at 42°C followed by 1 min cool 
down on ice. Next, LB medium was added to the bacteria-DNA mixture, followed by 1h 
incubation at 37°C and constant shaking. Finally, the bacteria were plated on agar 
plates containing antibiotic (100 μg/mL ampicillin), so that transformed cells could be 
selected, and incubated overnight at 37°C. Growing colonies on agar plates were 
randomly picked and allowed to grow in LB medium containing ampicillin. To validate the 
correct vector sequence, plasmid DNA was isolated with Qiaprep Spin Miniprep Kit 
(Qiagen), following the manufacturer’s instructions, and analysed by restriction enzyme 
digestion and gel electrophoresis. High quantity of pure plasmid DNA was purified with 
Endofree Plasmid Maxi Kit (Qiagen) and eluted in nuclease-free water. DNA plasmid 
sequence was finally confirmed by DNA sequencing (LGC Genomics). 
 
3.2.10 Generation of lentiviral vectors and cell transduction  
Lentiviruses containing genes of interest were produced in human HEK293T cells. 
Shortly, 11 μg of each expression construct were mixed with 8.25 µg of pCMV-dR8.91 
and 5.5 µg of pCMV-VSV-G lentiviral packaging constructs and with 50 µl of X-
tremeGENE™ 9 DNA transfection reagent (Sigma-Aldrich). This mixture was added to 
subconfluent HEK293T cells after 30 min incubations. Cell medium was discarded after 
12h, and collected after 24, 36 and 48h. Cell supernatant containing lentivirus was 
filtered through a 0.45 μm PVDF filter (Carl Roth) and either immediately used for cell 
transduction or aliquoted and stored at -80°C. The day before lentiviral infection (day 0), 
cells were seeded in 6-well plates. On day 1, cell medium was aspired and transduction 
medium, composed of 25% MEF medium and 75% lentivirus supernatant, was added to 
each well. Furthermore, 2-8 μg/mL polybrene (Sigma-Aldrich) were added to increase 
the transduction efficiency. At day 2, cells were re-infected with fresh transduction 
medium without polybrene. At day 4, cells were washed twice with PBS solution and 
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then exposed to culture medium supplemented with antibiotic (1-3 μg/mL Puromycin, 
Carl Roth; or 10-15 μg/mL Blasticidin, Sigma-Aldrich), accordingly with the used 
lentivirus. Cells were selected for about 3-5 d or until the un-transduced cells, exposed 
to the same selection antibiotic, completely died. Lentivirus production, collection, 
storage and cell infection procedures were all performed in a biosafety level II (“S2”) 
laboratory, according to the safety instructions. 
 
3.2.11 Cell proliferation and viability assay 
For proliferation assay, cells were seeded in 96-well plates at a density of 2.5-5x103 
cells/well, depending on the cell type and on the defined end-points of the experiments. 
24h after seeding, 10% of alamarBlue reagent (Invitrogen) was added to each well and 
after 4h incubation, fluorescence at the excitation wavelength of 560 nm and emission of 
590 nm was measured with a Tecan Infinite 200 spectrophotometer. To determine the 
cell proliferation rate, the same process was repeated every day until the 96h end-point. 
Cell viability upon drug treatment was assessed with a similar procedure. Again, cells 
were seeded in 96-well plates; the following day, cells were exposed to defined drugs 
(vemurafenib, Selleckchem; trametinib, Selleckchem; mithramycin A, Biotrend) alone or 
in combination treatments, at different concentrations, depending on cell type and 
exposure time. DMSO (Carl Roth) was used as control at 0.1% final concentration. 24 or 
48h after incubation, alamarBlue was added to cultured medium and fluorescence was 
detected. 
 
3.2.12 Migration assay 
Cells were trypsinized and then counted. 3.5x104 cells were seeded in both fields of 
culture-insert 2 well (Ibidi). The following day, inserts were removed to allow the cells to 
migrate towards the gap. 1 μg/mL aphidicolin (Sigma-Aldrich), a cell proliferation 
inhibitor, was added to the culture medium to avoid that gap closure speed was biased 
by cell proliferation. Cell migration was monitored at defined time points, until the gap 
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was fully closed, and images acquired with Nikon Eclipse Ti TIRF microscope and NIS-
Elements software. Migration rate was analysed with TScratch software (CSElab). 
 
3.2.13 Invasion assay 
Cell invasion was assessed with the Tumor Invasion System (Corning), following the 
manufacturer’s guidelines, with some modifications: cells were diluted to 5x104 cells/mL 
in 0.5% FCS-MEF medium and 500 μl of cell suspension was seeded in each top 
chamber. 20%FCS-MEF medium was added to the lower chamber to stimulate cell 
invasion. After 24h, invading cells were stained with 4 μg/mL calcein AM (Corning) in 
PBS solution for 1h. Then, images were acquired and fluorescence read. Cell invasive 
rate was quantified as relative fluorescence units (RFUs).  
Tumor cell invasive properties were also evaluated by establishing a 2D invasion 
system. Culture 2 well inserts were filled with about 3x104 melanoma cells on one side 
and 3x104 fibroblasts on the other. The following day, inserts were removed to allow the 
two cell types (both labelled with a different fluorochrome) to interact. Once the gap was 
fully closed, cells were exposed to inhibitor treatment. Images were acquired before and 
after treatment to define the amount of tumor cells which invaded the fibroblast layer 
under different conditions. 
 
3.2.14 Chromatin Immunoprecipitation (ChIP) and ChIP sequencing 
Chromatin immunoprecipitation was performed with the EZ ChIP kit (Merck Millipore), 
following the manufacturer’s protocol. Briefly, 1-2x106 cells were crosslinked with 3.6% 
formaldehyde for each chromatin immunoprecipitation, and then lysed on ice. Chromatin 
was sonicated using the Covaris S220 focused ultrasonicator and the so obtained 
sheared DNA was incubated overnight at 4°C with agarose bead-coupled antibodies. 
Next, immunoprecipitated chromatin was repeatedly washed and the crosslinks were 
released. DNA fragments were purified and amplified by quantitative PCR. Results were 
analysed by using the “% input” method. 
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For ChIP-seq experiments, about 10 ng of ChIP DNA fragments were used for library 
preparation by using NEB Next Ultra DNA Library kit (New England Biolabs) according 
to the manufacturer’s instructions. DKFZ Genomics and Proteomics Core Facility 
performed the library sequencing by using the Illumina Hiseq 2000 system, in 50-bp 
single-end mode. 
Sequence reads were aligned against the human reference genome (hg19), using the 
Bowtie mapping tool, allowing one mismatch and only unique reads in the analysis. 
Peak calling was conducted using MACS2 with a q-value cut-off of 0.05. Identification of 
differential binding sites was performed with Bedtools and Galaxy. Input-subtracted, 
whole-genome coverage tracks of aligned reads were generated and then visualized on 
Integrative Gene Viewer (IGV). 
 
3.2.15 Immunofluorescence 
3x104 cells were seeded in 8-chamber culture slides (Falcon). Once they reached 
subconfluency, cells were fixed in 4% PFA for 5 min on ice and additional 10 min at RT. 
Next, cells were washed with ice-cold PBA and permeabilized with 0.1 % Triton X-100 
(Carl Roth) for 10 min. To avoid unspecific signals, cells were pre-incubated with IF 
blocking solution before primary antibody incubation, overnight at 4°C. The following 
day, cells were washed and incubated with fluorescent dye-conjugated secondary 
antibodies for 2h at RT in the dark. Next, cells were stained with DAPI (Roche) and 
washed. Slide mounting was performed with fluorescence mounting medium (Dako). 
Images were acquired with a Nikon Eclipse Ti TIRF microscope using NIS-Elements 
software. 
 
3.2.16 Statistical analysis 
Experiments were run in triplicates, unless otherwise stated. Statistical analysis, 
performed using Prism 5.0 software (Graphpad), included the two-tailed Student’s t test 
to compare two conditions, one-way ANOVA to compare multiple conditions and data 
sets, spearman correlation to define the association of two parameters and Kaplan-
 
51 
 
Meier method for survival analysis. Data are represented as mean ± SEM and statistical 
significance is indicated with the p-value scale (“*” refers to a p- value <0.05; “**” for p-
value <0.01; “***” for p-value <0.001; “ns” refers to a p-value >0.5).  
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4 Results 
 
4.1 Gene expression analysis reveals putative downstream targets of 
SETDB1 
 
SETDB1 is a histone methyltransferase which modulates the trymethilation of lysine 
residue present on the N-terminal tail of histone H3. It has been reported that SETDB1 is 
widely expressed and contribute to the development of several cancer type, including 
melanoma. Previous work from our group demonstrated that SETDB1 was 
heterogeneously expressed in melanoma (Orouji, 2016). SETDB1 expression was 
assessed in a panel of human melanoma cell lines and they were categorized based on 
SETDB1 mRNA and protein levels as SETDB1 high- or low-expressing cells. In order to 
study the role of SETDB1 in melanoma, ectopic expression of SETDB1 was induced in 
low-expressing melanoma cells (HT144 and C32), by lentiviral transduction with a 
SETDB1-expressing construct (pLEX980-SETDB1). Following the establishment of 
stable cell lines overexpressing SETDB1 (hereafter named as SETDB1 OE cells), 
SETDB1 RNA and protein levels were evaluated in these cells in comparison to control 
cells transduced with the pLEX980-empty vector (EV) (Figure 7A). Next, gene 
expression profiling of SETDB1 EV (n=3 replicates) and SETDB1 OE (n=2) HT144 
melanoma cells was performed. Quantile-normalized microarray data showed that 
expression values of HT144 EV and SETDB1 OE cells clustered separately, defining 
two distinct profiles. Differential expression analysis (empirical Bayes two-group t test, 
log2 fold change threshold set as > 1, p-value 0.05) suggested that SETDB1 
overexpression led to profound changes in melanoma transcriptome (Figure 7B). 
Interpretation of microarray data was further implemented using a web tool based on the 
Gene Set Enrichment Analysis method (GSEA). GSEA allows the integration of 
expression data obtained by microarray experiments with phenotypic annotations 
referring to defined biological states. Genes upregulated in SETDB1 OE cells emerged 
as enriched in several gene sets which define conditions frequently linked to tumor 
development and progression, like cell proliferation (Gene ontology term GO:0042127; 
normalized enrichment score NES = 2.8, nominal p-value < 0.01, FDR < 0.01), cell 
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motility (GO:0048870; NES = 1.8, p-value = 0.01, FDR = 0.17), epithelial-to-
mesenchymal transition (GO:0001837; NES = 2.38, p-value < 0.01, FDR = 0.05) (Figure 
7C). This analysis suggested that SETDB1 overexpression induced a deregulation of 
factors which play crucial roles in cancer. This hypothesis was further supported by 
using the Ingenuity pathway analysis (IPA) tool, which compares molecular data with 
disease-associated and functional annotations. A wide range of cancer-related functions 
were predicted to be activated upon SETDB1 upregulation (Figure 7D; IPA functional 
annotation’s details are described in Table 1). Therefore, expression data of SETDB1-
overexpressing melanoma cells gave the first hints that SETDB1 might act as a gene 
regulator. 
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Figure 7: SETDB1 upregulation led to drastic transcriptome changes in melanoma cell lines.A) 
Validation of SETDB1 overexpression in C32 and HT144 melanoma cell lines by western blot (WB) 
analysis. Immunoblotting showed an increase of SETDB1 protein signal. GAPDH was used in this 
experiment as internal control. B) Heat map of microarray data showing differentially expressed genes 
between HT144 empty vector (EV) and HT144 SETDB1-overexpressing (SETDB1 OE) cells. C) GSEA 
analysis of significantly deregulated genes found in HT144 SETDB1 OE cells. Top panel showing the 
enriched GSEA plots related to cell proliferation, cell motility and epithelial-to-mesenchymal transition 
mechanisms, together with enrichment scores (ES) and false discovery rate (FDR) values. Positive 
enrichment scores indicate a concordance between the microarray gene expression values and the gene 
set-related biological state. In this case, top-upregulated genes in SETDB1 OE cells were predicted to 
promote cell proliferation, motility and EMT. Bottom panel, representation of the top-deregulated genes 
linked to the above mentioned enriched gene sets. D) IPA biological pathway analysis of deregulated 
genes in SETDB1 OE cells. Several biological functions related to cancer were found activated (showing a 
positive Z score) upon SETDB1 upregulation. More details about the top-ranked enriched annotated terms 
are included in Table 1.  
 
4.2 THBS1, a known marker of melanoma progression, is regulated by 
SETDB1 in melanoma cell lines 
 
As shown in the previous paragraph, several pro-tumorigenic and pro-metastatic factors 
were upregulated following SETDB1 overexpression, suggesting that these factors may 
act as SETDB1-downstream targets. Further analysis of the expression profiles of 
SETDB1-overexpressing melanoma cells indicated that among the upregulated genes 
the ones encoding for pro-tumorigenic secreted factors, including thrombospondin 1 
(THBS1), secretogranin 2 (SCG2), metalloproteinases 1 and 3 (MMP1, MMP3), 
interleukin 6 and 8 (IL6, IL8), wnt family member 5a (WNT5A) and C-C Motif Chemokine 
Ligand 2 (CCL2) were particularly enriched (Figure 8A). Amongst the top-ranked 
candidate genes identified by microarray and gene enrichment analysis was the THBS1 
gene (FC = 2.31 in SETDB1 OE vs EV). THBS1 is a glycoprotein involved in the 
progression of several cancer types. In melanoma, THBS1 strongly contributes to 
promote cell invasiveness and metastasis formation (Jayachandran et al, 2014). 
Because of the particular role of THBS1 in melanoma and the observed upregulation in 
melanoma cells with high levels of SETDB1, which has been also linked to an 
aggressive phenotype, I hypothesized that there might be a possible regulatory axis 
between SETDB1, as master regulator, and THBS1, as effector. For this reason, a 
comprehensive approach was adopted to further confirm and characterize the 
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relationship between these factors. Besides the establishment of stable melanoma cell 
lines with ectopic SETDB1 expression, loss-of- function studies based on SETDB1 gene 
expression silencing were also conducted. In our laboratory the SK-HI-SETDB1 
melanoma isogenic cell line was previously established from SKMEL 28 melanoma 
cells. This cell line is characterized by multiple amplifications of the SETDB1 gene locus 
and high endogenous SETDB1 expression level (Orouji, 2016). SK-HI-SETDB1 cells 
were infected with lentivirus carrying a SETDB1-specific shRNA construct (referred to as 
“SETDB1 KD”). In parallel, cells were also transduced with a non-targeting lentiviral 
shRNA construct (“NT”), as control (Figure 8B and 8C). Established overexpressing 
and knockdown melanoma cell lines were tested for THBS1 expression. The THBS1 
levels was altered by SETDB1 deregulation, observing a prominent increase in SETDB1 
OE and a reduction in SETDB1 KD cells, compared with the respective controls (Figure 
8D and 8E). As a further confirmation, SETDB1 EV and OE C32 cells were 
subcutaneously injected into immunodeficient NOD-SCID mice to allow tumor formation 
and growth. Next, tumors were excised; sliced and paraffin-embedded sections were 
then stained for SETDB1 and THBS1. Interestingly, SETDB1 expression co-localized 
with THBS1 expression, showing an intense signal in xenograft tissue derived from 
SETDB1 OE C32 cell lines (Figure 8F).  
 
Finally, to ascertain the role of THBS1 as a SETDB1 target and as an effector in 
melanoma progression, functional properties of SETDB1 OE HT144 melanoma cells 
with a THBS1 knockdown (“THBS1 KD”) (Figure 9A and 9B) was evaluated. THBS1 
knockdown in these cells severely impaired the migratory capacity (Figure 9C), implying 
that THBS1 is required for SETDB1-driven migration mechanisms and, therefore, that 
SETDB1 exerts its pro-tumorigenic role by regulating downstream targets like THBS1. 
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Figure 8: SETDB1 regulated the expression of THBS1 in melanoma cell lines.A) Histogram plot 
showing microarray expression data (expressed as Log2 fold change) of genes encoding for THBS1, 
SCG2, MMP1, MMP3, IL6, IL8, WNT5A and CCL2 in HT144 SETDB1 OE cells compared with EV cells. 
Presented genes were sorted by protein family/ biological functions. B) Real time quantitative PCR (RT-
qPCR) showing SETDB1 transcript levels in SK-HI-SETDB1 cells following lentiviral transduction with 
shRNA against SETDB1 (SETDB1 KD) or with a non-targeting shRNA (NT). Fold change indicates the 
relative expression change for SETDB1 in knockdown cells compared with the control condition, whose 
relative expression was set as 1. C) Representative western blot of SETDB1 and GAPDH (used as 
control) in NT and SETDB1 KD cells. D) qPCR Analysis of THBS1 expression in SETDB1 OE and KD 
melanoma cells, in comparison to the respective controls. E) Western blot analysis of THBS1 expression 
in SETDB1-dysregulated melanoma cells. F) Immunohistochemical (IHC) staining of SETDB1 and THBS1 
in paraffin-embedded tumor sections derived from NOD/SCID null mice xenografts obtained after injection 
of C32 EV or SETDB1 OE cells. Scale bar: 100 µm. The bottom-right frames show zoomed-in 
acquisitions.  
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Figure 9: Knockdown of THBS1 in SETDB1 high-expressing melanoma cells impaired the tumor 
cell migration properties.A) and B) Validation of THBS1 knockdown (THBS1 KD) efficiency in SETDB1 
OE (HT144) melanoma cells using quantitative PCR and western blot. C) Wound healing assay performed 
with HT144 SETDB1 OE cells following THBS1 silencing. The top-panel shows representative images 
acquired after 0 and 24 hours, indicating the impaired migratory capacity after knockdown of THBS1. The 
bottom panel depicts the quantification of the wound healing assay. 
 
 
4.3 THBS1 positively correlates with SETDB1 expression in melanoma 
clinical samples 
 
The association between SETDB1 and THBS1 was also investigated in melanoma 
patients’ tumor biopsies. Tissue microarray analysis (TMA) allowed us to screen a large 
number of patients’ biopsies. This study included 41 biopsies derived from primary 
melanomas and 54 metastatic melanoma samples. SETDB1 and THBS1 signals were 
scored according to the immunohistochemistry (IHC) score system (Wagner et al, 2015). 
This test takes into account the signal intensity (scored in a range from 1-3) and 
 
58 
 
abundancy (i.e. percentage of positive cells; score range: 0-4) for each sample. The final 
IHC score obtained by multiplying the scores for the two parameters indicates the 
protein expression levels in tumor tissues. I aimed at observing correlations between 
SETDB1 and THBS1 expression in patients’ biopsies and, strikingly, it was possible to 
observe a positive correlation of their expressions in primary (Spearman correlation r = 
0.39, p value = 0.0106) and metastatic melanoma (r = 0.5234, p <0.01) cohorts (Figure 
10A and 10B). Of note, SETDB1 and THBS1 signals mostly co-localized at the outer 
regions of the lesions, corresponding to the tumor invasive front (Figure 10C). Taken 
together, THBS1 expression was linked with SETDB1 expression also in clinical 
samples derived from malignant melanoma patients, adding a prominent prognostic 
value to this newly established axis.  
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Figure 10: Analysis of SETDB1 and THBS1 expression and localization in patient-derived tumor 
biopsies. A) Tissue microarray analysis (TMA) of a cohort of melanoma patients showed that SETDB1 
expression positively correlated with THBS1 expression in tumor tissue samples derived from A) primary 
melanomas (n = 41), and B) melanoma metastases (n = 54). On the left panel, the SETDB1 and THBS1 
correlation plot is shown. Number of analysed samples (n), Spearman correlation coefficient (r) and p 
value are reported. On the right side, representative images of patient-derived tissue biopsies stained for 
SETDB1 and THBS1 are depicted. Tumors characterized by intense SETDB1 staining showed also a high 
THBS1 signal. Conversely, primary melanoma and metastases specimen exhibiting a weak signal for 
SETDB1 also showed a weak staining for THBS1. C) THBS1 IHC staining of primary melanoma-derived 
tissue. As previously observed for SETDB1 (Orouji, 2016), THBS1 expression is particularly enhanced in 
the external regions (also described as “invasive” tumor front), compared to the internal regions (“non-
invasive” front). Negative staining validated the specificity of the THBS1 antibody. Scale bar: 100 µm. 
 
 
4.4 SETDB1 limits the expression of melanocytic lineage-differentiation 
and anti-metastatic genes  
 
Gene expression data showed that several factors were downregulated in melanoma 
cells upon SETDB1 induction (Figure 11A). Functional annotation of these gene was 
performed by using the web tool DAVID and the analysis showed that the top-enriched 
DAVID annotation terms were mostly associated with melanocytic differentiation and 
metabolism, like melanin biosynthesis (GO: 0042438), melanosome formation (GO: 
0033162) and developmental pigmentation (GO: 0048066) (Detailed list of biological 
functions downregulated in SETDB1 OE cells is given in Table 2). During the transition 
from melanocytes to melanoma, a loss of differentiation properties occurs towards a 
more undifferentiated status (Lekmine et al, 2007; Pinner et al, 2009). This process goes 
along with the downregulation of the differentiation markers, most of which act as tumor 
suppressors and anti-metastatic factors. Following SETDB1 overexpression, a reduction 
of melanogenesis-related and metabolic proteins, involved in anti-tumorigenic and anti-
metastatic processes, was observed. In particular, DCT showed a negative correlation 
with SETDB1 in melanoma cell lines (Figure 11B and 11C). The obtained data indicate 
that SETDB1 might interfere with the expression of pro-differentiation and tumor 
suppressor factors.  
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Figure 11: Increasing levels of SETDB1 reduced the expression of melanocytic and metabolic 
markers.A) Expression data (obtained from the microarray analysis of EV vs SETDB1 OE cells) of the 
pro-differentiation genes DCT, TYRP1, TYR, PMEL17 genes (grey bars) and of metabolic factor-encoding 
ALDOC and APOE genes (black bars), following SETDB1 induction. B) Validation of DCT mRNA levels in 
in SETDB1-overexpressing (C32 and HT144) cell lines. C) DCT western blots of SETDB1 OE and 
knockdown (SK-HI-SETDB1) cells, with respective controls. Detected DCT band size at ~59 kDa. Beta 
actin was used as loading control. 
 
 
4.5 Methyltransferase-deficient SETDB1 impairs the expression of its 
downstream targets  
 
Although SETDB1 has already been described to be involved in tumor progression in 
several cancer types, little is still known about how this protein mechanistically acts. As 
already mentioned, the SETDB1 protein is structurally divided into distinct domains, 
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each of which responsible for specific activities. In particular, the SET domain is 
essential for the histone methyltransferase (HMT) function. To determine whether the 
influence of SETDB1 on melanoma progression is HMT activity-dependent, a loss-of-
function approach based on SET domain inactivation was carried out: two specific SET 
domain amino acids were substituted by site-direct mutagenesis. As indicated by Ceol et 
al. (PMC3348545), the H1224A and C1226K mutations completely inactivate SET 
domain activity. The mutated SETDB1 coding sequence (Figure 12A) was inserted into 
pLEX980 lentiviral expression vector and the construct was used for the transduction of 
melanoma cells. Mutated SETDB1 (HC/KA SETDB1 OE) was overexpressed in C32 and 
HT144 melanoma cells. In contrast to overexpression of wild-type SETDB1, total levels 
of trimethylated histone H3 at lysine 9 (H3K9me3) did not increase upon overexpression 
of HC/KA (Figure 12B and 12C). With this methyltransferase-deficient variant of 
SETDB1, molecular and biological perturbations caused by SETDB1 expression in 
melanoma were investigated. A whole-genome expression profiling was performed for 
SETDB1 OE (number or replicates=2) and HC/KA SETDB1 OE (n=3) HT144 cells. Gene 
expression data obtained by this microarray analysis (empirical Bayes two-group t test, 
log2 fold change filtering threshold > 1, p-value 0.05) showed different transcriptome 
profiles accordingly with SETDB1 mutational status. Interestingly, the most significantly 
differentially expressed genes between the two groups were the same that have been 
shown to be differentially expressed between melanoma cells transduced with wild-type 
SETDB1 and EV (Figure 12D). To validate these findings, the expression of SETDB1 
target genes was examined. Remarkably, HC/KA SETDB1 did not induce THBS1 
expression. In contrast, expression of the pro-differentiation gene DCT was not 
decreased in cells overexpressing HC/KA SETDB1 compared to cells overexpressing 
wild-type SETDB1 (Figure 12E and 12F). These data indicate that the role of SETDB1 
as a master regulator is greatly dependent on SET domain integrity and functionality. 
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Figure 12: SET domain inactivation restrained as the capacity of SETDB1 to regulate the 
expression of its downstream targets. A) Sequence comparison between wild-type and 
methyltransferase-deficient variant of SETDB1 showing the nucleotide substitutions which resulted in SET 
domain inactivation. B) Western blot assessment of SETDB1 and H3K9me3 expression in C32 and 
HT144 melanoma cell lines infected with EV-, SETDB1 OE and HC/KA SETDB1 OE lentiviral constructs. 
GAPDH and beta actin were used as loading controls, respectively. C) Immunofluorescent detection of 
H3K9me3 in SETDB1 OE and HC/KA SETDB1 OE cells. DAPI was used for nuclear staining. Scale bar: 
100 µm. D) Heat map image of a microarray analysis comparing the transcriptomic profiles of melanoma 
cells overexpressing wild-type vs mutated SETDB1. Microarray expression data were confirmed by 
measuring THBS1 and DCT mRNA E) and F) protein expression, respectively, in C32 and HT144 
SETDB1 OE cells in comparison to HC/KA SETDB1 OE cells. Western blot loading control: α-actinin. 
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4.6 SETDB1 HMT inactivation results in a less aggressive phenotype of 
melanoma cells 
 
Differentially expressed genes between melanoma cells expressing HC/KA SETDB1 or 
wild-type SETDB1 are strictly linked with cancer-related phenotypic states. By using 
GSEA tool, gene sets related to cell motility (GO: 0048870) and activation (GO: 
0050865) were found to be overrepresented, showing in this case a negative enrichment 
score (NES) in HC/KA SETDB1 OE cells vs SETDB1 OE cells (NES = -2.19, p-value 
<0.01, FDR = 0.004 for cell motility gene set; NES = -2.35, p-value <0.01, FDR = 0.002 
for cell activation annotation term). This means that genes known to promote tumor cell 
motility and tumor activation were not upregulated in melanoma cells expressing 
mutated SETDB1 in contrast to cells expressing wild-type SETDB1 (Figure 13A). 
Ingenuity pathway analysis (IPA) provided further hints supporting the hypothesis that 
eliminating the methyltransferase activity of SETDB1 contributed to the reduction of 
SETDB1-mediated pro-invasive and pro-metastatic properties and an increase of 
melanocyte-specific differentiation (Figure 13B; IPA functional annotation’s details are 
described in Table 3). To confirm these observations, in vitro cell-based functional 
assays with HC/KA SETDB1 OE C32 and HT144 cells were performed. SETDB1 OE 
cells were used as a control for the following experiments. We could not observe any 
drastic differences in melanoma cell proliferation between the two cell populations after 
24-96h of observation (Figure 14A). Next, the migration capacity was evaluated with the 
scratch assay, which indicated a slower migratory capacity of HC/KA SETDB1 OE cells 
compared with the control (Figure 14B). Additionally, the transwell cell invasion assay 
showed how the inactivation of the SET domain strongly affected the invasive properties 
of melanoma cells (Figure 14C). Taken together, abrogating the methyltransferase 
activity of SETDB1 by introducing specific point mutations in its SET domain led to a 
reduction of progression-related functional features of melanoma cells, which might be 
the likely due to the dysregulation of SETDB1 target genes involved in pro-migratory and 
pro-invasive mechanisms.  
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Figure 13: In silico prediction of SETDB1’s HMT inactivation functional effects.A) GSEA plots and 
corresponding gene set lists, describing a negative enrichment score obtained by integrating gene 
expression data (HC/KA SETDB1 OE vs SETDB1 OE cells) with cancer-related gene set annotations. 
Negative ES indicates that genes which are normally involved in tumor cell activation and motility were 
found to be downregulated in HC/KA SETDB1 OE cells compared with cells overexpressing wild-type 
SETDB1. B) IPA pathway and biological feature analysis, predicting an activation (positive Z score) of 
melanocyte-specific biological processes (i.e. melanocyte development and pigmentation signalling), in 
concomitance with a strong reduction (negative Z score) of tumor-related features, like cell movement 
(including migration, invasion, extravasation, metastases formation). More details about the top-ranked 
enriched annotated terms related to cell movement are included in Table 3. 
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Figure 14: HC/KA SETDB1 OE melanoma cells exhibited a remarked impairment of proliferative 
and migrative capacity. A) Alamarblue assay performed with HC/KA SETDB1 OE and SETDB1 OE 
cells. Cell proliferation was observed from day 1 to day 5. Proliferative rate was measured as quantity of 
fluorescence emission following Alamarblue substrate exposure. B) Migration scratch assay performed 
with melanoma cells (C32 and HT144), transduced with either SETDB1 OE or HC/KA SETDB1 OE 
lentiviral construct. Migratory capacity of the cells was quantified by measuring the percentage of open 
gap area observed at each time point compared to 0h. In the case of C32 (slowly migrating cells), the 
experiment was extended until the 48h-time point. Images scale bar: 500 µm. C) Melanoma cell invasion 
rate was assessed with the transwell invasion system. 24-48h after seeding the invading cells were 
exposed to calcein AM fluorescent dye. Fluorescence emission was observed (top panel) and quantified 
(bottom panel) as relative fluorescence units (RFUs). Invasion plate wells with no seeded cells were used 
as background control. 
 
 
4.7 SETDB1 regulates THBS1 via alterations in histone methylation 
patterns 
 
The data presented here support a crucial role for SETDB1 in regulating the expression 
of important pro- and anti-tumorigenic factors during melanoma development. Next, I 
aimed at elucidating the molecular mechanisms of SETDB1 by which it exerts its 
functions. As a histone methyltransferase SETDB1 contributes to the modification of 
chromatin structure. Alterations of chromatin structure and chromatin-associated 
components have been found to directly mediate drastic changes at the molecular level, 
i.e. gene expression (Bilodeau et al, 2009). For that reason, I wanted to identify altered 
chromatin states that were linked with SETDB1 expression during melanoma 
progression. In particular, the investigations focused on histone methylation patterns 
which were directly involved in regulating gene expression. By performing chromatin 
immunoprecipitation (ChIP) and ChIP-sequencing (ChIP-seq), I analyzed the global 
distribution and local enrichment of specific histone marks: trimethylated histone H3 at 
lysine 9 (H3K9me3), a histone modification directly mediated by SETDB1 and 
monomethylated H3 at lysine 4 (H3K4me1). The H3K4me1 histone modification is found 
particularly enriched at active gene enhancer sites and plays a pivotal role in 
determining chromatin state-based gene expression alterations (Heintzman et al, 2007). 
Furthermore, an inverse correlation between SETDB1-induced H3K9me3 and the K4 
methylation status (Binda et al, 2010) as well as between SETDB1 expression and 
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H3K4me1 distribution have been recently described (Perner et al, 2014). Chromatin 
obtained from SETDB1 OE (C32) and SETDB1 KD (SK-HI-SETDB1) cells and from the 
corresponding controls was immunoprecipitated with antibodies against H3K9me3 and 
H3K4me1. Immunoprecipitated chromatin was then de-crosslinked and resulting DNA 
fragments were amplified and assembled in DNA libraries, before multiplex sequencing 
(n = 2 sequencing experiments conducted). ChIP-seq raw reads were mapped to human 
genome (hg19 used as reference), and regions enriched for the investigated histone 
marks were marked by peaks. Large-scale histone methylation profiling included the 
analysis of global number of enriched areas and of the peak regions surrounding the 
regulatory sites of SETDB1 targets. First, following the alteration of SETDB1 expression, 
profound changes of genome-wide H3K9me3 abundancy occurred. SETDB1 
overexpression induced a massive increase of detected H3K9me3-binding sites (unique 
peaks observed in C32 EV cells: 3.528; unique peaks in C32 SETDB1 OE cells: 
19.510), while SETDB1 silencing severely affected the global H3K9me3 levels 
(H3K9me3 ChIP-seq performed on SK-HI-SETDB1 NT cells resulted in 52.203 unique 
peaks, whereas only 13.877 enriched regions were exclusively found in SETDB1 KD 
cells) (Figure 15A). These data suggest that SETDB1 might be particularly relevant in 
melanoma for determining and regulating the trimethylated histone H3 at lysine 9 status. 
Local H3K9me3 enrichment analysis did not show any differential H3K9me3 enrichment 
patterns in genomic regions corresponding to the genes previously shown to be 
regulated by SETDB1. However, by exploring the genome distributions of the H3K4me1 
mark, it was possible to observe that H3K4me1 enrichment profiles were altered, in 
correspondence with SETDB1 expression levels, at specific regulatory sites of the 
THBS1 gene. Strikingly, in melanoma cells overexpressing SETDB1, low levels of 
H3K4me1 surrounding THBS1 regulatory regions were observed, whereas in cells 
exhibiting low amounts of SETDB1, H3K4me1 marks were significantly enriched around 
the THBS1 gene locus (Figure 15B). ChIP-qPCR experiments further confirmed these 
observations: H3K4me1 ChIP DNA samples, together with relative input samples 
(containing the pre-immunoprecipitation DNA), were amplified with specifically designed 
primers annealing to H3K4me1-enriched regions nearby the THBS1 transcription start 
site (chr15:39,870,657-39,871,729). Results showed that SETDB1 repression increased 
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the amount of H3K4me1 marks. No differences were detected for the GAPDH promoter 
region which was used as control in this experiment (Figure 15C). These results support 
the role of SETDB1 as a regulator of THBS1. Mechanistically, SETDB1 expression 
resulted in drastic epigenetic alterations in melanoma cells. Regarding the histone 
modifications associated with altered gene expression, my experiments suggest that 
SETDB1 specifically altered the expression of its target by affecting the H3K4me1 
distribution and enrichment patterns.  
 
Figure 15: Identification of epigenetic traits altered by SETDB1 deregulation.A) Venn diagrams 
showing the number H3K9me3-related peaks detected with ChIP-seq performed with EV /SETDB1 OE 
 
69 
 
(C32) cells and NT/SETDB1 KD (SK-HI-SETDB1) cells. Indicated values refer to the quantity of genomic 
sites where H3K9me3 exclusively binds in each condition, while the diagrams’ intersection regions are 
related to the common peaks. Upon SETDB1 induction, the percentage of H3K9me3 enriched regions 
drastically increased, while SETDB1 KD led to a pronounced loss of genome-wide H3K9me3 distribution. 
B) IGV visualization of H3K4me1 distribution profiles at the THBS1 locus. SETDB1 overexpression led to 
a low levels of trimethylated H3K4 at genomic regions corresponding to THBS1 gene, while SETDB1 
silencing resulted in the increase of H3K4me1 distribution and enrichment at THBS1 regulatory sites. C) 
Real-time quantitative PCR of H3K4me1 ChIP DNA. Primers annealing with the THBS1- and GAPDH-
(control) promoter were used to quantify H3K4me1 enrichment at those particular genomic sites in 
immunoprecipitated chromatin, compared with input samples. Quantifications were performed using the 
percent input method. 
 
 
4.8 Mithramycin A treatment reduces SETDB1 levels and melanoma cell 
viability 
 
From the results of my study, one can conclude that SETDB1 might play an important 
role during melanoma progression. For this reason, the next aim of this project was to 
establish a drug-based approach able to target SETDB1 expression in order to abrogate 
its melanoma promoting effect. Although a selective SETDB1 inhibitor has not been 
identified yet, SETDB1 expression could efficiently be blocked by the antitumoral drugs 
paclitaxel (Noh et al, 2014) or by unspecific histone methyltransferase inhibitors, like 
DZnep (Lee & Kim, 2013) and mithramycin A (Ryu et al, 2006) (Karanth et al, 2017). 
Within the scope of this study, mithramycin A (mit) was chosen for blocking SETDB1. Mit 
is an antitumor antibiotic widely used in clinical trials (Phase 2) for the treatment of 
several cancer types (ClinicalTrials.gov Identifier: NCT01624090).Functionally, mit is a 
DNA-binding factor that represses SETDB1 expression by competing with the 
transcription factor SP-1 for binding sites within the SETDB1 promoter region (Choi et al, 
2014). I tested the mit capacity to specifically inhibit SETDB1 in melanoma cells by 
exposing melanoma cells with high SETDB1 expression levels (A375, SK-HI-SETDB1) 
to different mit concentrations (1 nM - 2 µM range) for 24 and 48h. Both cell lines 
showed high sensitivity to the treatment (mean IC50 values for A375: 866.8 nM after 24h 
of treatment, 38.45 nM after 48h of observation; IC50 SK-HI-SETDB1: 473.8 and 41.99 
nM after 24 and 48h, respectively) (Figure 16A). Human dermal fibroblasts and 
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SETDB1 KD melanoma cells did not respond to the treatment (Figure 16B and 16C), 
suggesting that mit affects melanoma cells by blocking SETDB1. To further ascertain 
whether mit-mediated reduction of melanoma cell viability was related to SETDB1 
inhibition, the SETDB1 expression levels in response to increasing concentrations of mit 
were assessed. After 24h of treatment, the SETDB1 RNA and protein level decreased 
gradually in accordance with the increment of mit doses. Following 24h of treatment with 
300 nM mit, SETDB1 was almost totally silenced (for qPCR analysis, One-way ANOVA 
test was applied; p-value <0.0001) (Figure 17A and 17B). No further reduction of 
SETDB1 expression was observed with higher mit dosages. 24h exposure to 300 nM mit 
was established as the standard mit treatment for all the subsequent drug response 
experiments.  
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Figure 16: Melanoma cells showed great sensitivity to mithramycin A.A) Dose response curves of 
A375 and SK-HI-SETDB1 cells treated with increasing concentrations (nM) of mit for 24 and 48h. The 
viability of the cells treated with the vehicle control (DMSO) was set as 100%. B) Alamarblue assay to 
determine the viability of SETDB1 KD melanoma cells compared with the NT control upon 24h of mit 
exposure. C) Viability assay performed with dermal fibroblasts and two different melanoma cell lines 
treated with different mit concentrations for 24h. 
In addition to an impairment of cell growth capacity, drastic changes in melanoma cell 
morphology were noted. Parental A375 cells appear like small and epithelioid cells, 
while SK-HI-SETDB1 cells (derived from the cell line SKMEL28) are bigger in size and 
possess dendritic structures. Upon mit exposure, both cell lines showed an altered 
morphology, with increased size, larger nuclei, reduction of cell-cytoplasm ratio and, for 
SK-HI-SETDB1 cells, less dendritic structures (Figure 18). From my data, one can 
conclude that mit reduced melanoma cell viability and altered their morphology via 
inhibiting SETDB1, which is specifically targeted by mit in a dose-dependent fashion. 
 
 
Figure 17: Mithramycin A completely abolished SETDB1 expression in melanoma cells.A) qPCR 
analysis of SETDB1 expression in A375 cells exposed to DMSO (control) and to increasing doses of mit 
for 24h. SETDB1 transcript levels decreased with increasing concentration of mit. B) Western blot 
detection of SETDB1 in A375 and SK-HI-SETDB1 cells showed a mit dose-dependent inhibition of 
SETDB1 expression 
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Figure 18: Mithamycin A treatment induced distinct morphological changes in melanoma cells. 
Following 300 nM mit-exposure for 24h, A375 and SK-HI-SETDB1 cells exhibited changes of cell size, 
shape and microscopic structures. Cells were magnified 40x and 100x with a light microscope. 
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4.9 Mithramycin A inhibition reverts the regulatory effect of SETDB1 on the 
expression of its downstream effectors 
 
The consequences of mit-mediated SETDB1 inhibition were further analysed by 
evaluating variations in the regulatory network of SETDB1. A375 and SK-HI-SETDB1 
cells were treated with 300 nM mit for 24h and afterwards the expression of SETDB1 
downstream factors was assessed. It could be shown that the expression of pro-
tumorigenic genes like THBS1, SCG2, MMP3, IL6, and CCL2 was impaired. On the 
other hand, factors that were previously identified as “anti-metastatic”, such as DCT, 
TYRP1, ALDOC and APOE displayed a strong induction (Figure 19A and 19B). These 
data further confirmed that several factors involved in cancer progression were regulated 
by SETDB1 and that SETDB1 inhibition led to the dysregulation of SETDB1-driven 
regulatory mechanisms. I also examined the H3K4me1 alterations related to SETDB1 
expression in A375 cells following mit treatment. Focusing on the previously identified 
H3K4me1-binding region at the THBS1 promoter, it was possible to observe an 
enrichment of this histone mark upon drug treatment, mimicking the same epigenetic 
effect observed in SETDB1 KD cells (Figure 19C). I exploited the drug-based SETDB1-
silencing approach to investigate the SETDB1-mediated DCT regulation. Although 
chromatin studies performed in this work did not reveal any alterations of chromatin 
state in the regulatory regions of the DCT gene, my data still indicate that SETDB1 
impacts DCT expression on the transcriptional level. To test this hypothesis, the TRP2-
lenti gene reporter plasmid was generated. TRP2-lenti is constituted of about 900 bp of 
the DCT promoter region containing melanocyte-specific cis-elements (Yokoyama et al, 
1994) placed in front of the ORF of GFP. This construct was transduced in A375 and 
SK-HI-SETDB1 cells, which exhibit high endogenous SETDB1 and very low 
endogenous DCT expression. Consequently, transfected cells emitted no or only a very 
faint green fluorescence signal. However, following mit exposure, a general increase of 
the GFP signal was detected (Figure 19D). These data suggest that high SETDB1 
expression suppresses DCT expression at the molecular level and, once SETDB1 was 
silenced, DCT was actively transcribed. 
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Figure 19: Gene expression analysis of melanoma cells following Mithramycin A-mediated 
SETDB1 inhibition.A) qPCR analysis of SETDB1 candidate downstream targets in A375 treated either 
with DMSO or with 300 nM mit. B) Immunoblotting for THBS1, DCT and GAPDH in the lysate of A375 
cells treated with either DMSO- or mit. C) H3K4me1 ChIP-qPCR analysis of the THBS1 promoter region 
was performed in A375 cells cultured in the presence or absence of mit for 24h. Amplification of the 
GAPDH promoter served as a negative control. Plot represented the percentage of chromatin 
immunoprecipitated with a H3K4me1-specific antibody versus the total chromatin (input). D) Detection of 
GFP signals in A375 and SK-HI-SETDB1 melanoma cells, transduced with the TRP2-lenti construct and 
treated with 300 nM mit or DMSO by using fluorescence microscopy. 
 
SETDB1-mediated secretory mechanisms may be affected by mit treatment. For this 
reason, proteome profiling of treated vs untreated cells was performed. Of note, mit-
treated A375 cells showed a significant reduction of MMP8, IL8 and CCL2 secretion, 
while THBS1 secretion was not altered (Figure 20). Mit-mediated SETDB1 inhibition 
affected molecular mechanisms in melanoma, contributing to a drastic shift from an 
aggressive tumor cell-like behaviour towards a more differentiated phenotype. 
 
Figure 20: Downregulation of SETDB1 expression resulted in a decreased secretion of MMP8, IL8 
and CCL2.Secretome analysis of A375 cells cultured for 1 day in the presence or absence of 300 nM mit 
performed with the Proteome profiler assay. Upper panel shows the mean pixel density of 55 different 
secreted proteins detected in the supernatant of cultured cells; MMP8 (blue circles), IL8 (green), CCL2 
(red) and THBS1 (black) signals are highlighted. Lower panel displays the reduction of secretion of MMP8, 
IL8, CCL2 and THBS1 from cells exposed to mit, compared with the ones treated with DMSO. 
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4.10 Functional characterization of mithramycin A-treated melanoma cells  
 
Knowing that mit treatment altered the expression of SETDB1 and its downstream 
targets in melanoma, I started examining the functional implications of this drug-induced 
process. As previously shown, SETDB1 knockdown or inactivation of its catalytic domain 
led to an impairment of the biological features mostly associated with aggressive tumor 
development and metastases formation, like cell motility, migration and invasion. I 
performed cell-based functional assays to ascertain whether mit treatment affects the 
migratory and invasive capacities of melanoma cells. Scratch wound healing and 
transwell invasion assays confirmed that mit-induced SETDB1 deprivation resulted in 
important reduction of cell motility, together with a drastically decreased invasion 
capacity (Figure 21A and 21B). To further investigate melanoma cell behaviour under 
the influence of the tumor microenvironment, a 2D invasion model was established. This 
system consists of a co-culture of melanoma cells and dermal fibroblasts. Previously, 
both cell types were fluorescently labelled by transduction with a lentiviral reporter 
constructs for fluorescence (GFP was constitutively expressed by melanoma cells, while 
fibroblasts expressed Tomato red fluorescent protein) to subsequently track them during 
the co-culture experiments. Initially, the two cell types were separated by a wound gap, 
allowing the cells to migrate towards each other. When the gap was fully closed, tumor 
invasive cells started to interact with fibroblasts and to invade the fibroblast layer that is 
composed of cells and extracellular matrix components released by fibroblasts. At this 
specific time point, mit was added (Figure 22A). Comparing the amount of invasive cells 
exposed to mit or DMSO (control) after 24 h showed significantly less mit-treated tumor 
cells scattered across the fibroblast layer compared with the control (Figure 22B). This 
indicated that the mithramycin A not only impaired the intrinsic migratory properties of 
the tumor cells, but also their capacity to interact with components of the tumor 
microenvironment. The impairment of the migratory and invasive properties of 
melanoma cells might be due to the deregulation of migration- and invasion-related 
proteins upon mit-mediated SETDB1 inhibition. Taken together, mit treatment led to a 
less aggressive melanoma cells phenotype characterized by reduced cell motility and 
invasive capacity. 
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Figure 21: Migration and invasion analysis of melanoma cells exposed to mithramycin A.A) 
Quantification of the migration capacity of melanoma cells treated with DMSO or mit. On the left panel, 
representative images of scratch assays with A375 cells. On the right side, quantification of open gap area 
on scratched A375 and SK-HI-SETDB1 cell layers after 24h of stimulation. B) Transwell assay showing a 
strong reduction of invasion capacity of mit-treated melanoma cells. On the left side, microscopic images 
of invading fluorescent cells after DMSO- or mit-treatment. On the right side, quantification of the invasion 
rate for A375 and SK-HI-SETDB1 cells following mit exposure, measured as the relative fluorescence 
units (RFUs) released from these cells in comparison to DMSO-treated invading cells. 
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Figure 22: Mithramycin A limited the interactions of melanoma cells with dermal fibroblasts.A) 
Schematic overview of the 2D invasion system. B) Fluorescent images of 2D invasion assays. Melanoma 
cells and fibroblasts were co-cultured and subsequently exposed to 300 nM mit (or DMSO). After 24h, the 
number of tumor cells that have invaded the fibroblast layer was evaluated. A375 cells showed a massive 
invasive behavior, impaired by mit treatment. SK-HI-SETDB1 cells were able to disseminate within the 
fibroblast layer- Also in this case, mit totally inhibited the invasive capacity of SK-HI-SETDB1 cells (green 
dots observed at the front of the fibroblast layer were mostly non-viable tumor cells). 
 
 
4.11 Combinatorial treatment of melanoma cells with mithramycin A and 
vemurafenib/trametinib enhanced the efficacy of targeted therapy 
 
In order to find out if the application of mithramycin A might be a reasonable option for 
the treatment of melanoma, it was tested in combination with well-established targeted 
therapy compounds used in melanoma therapy. A375 and SK-HI-SETDB1 cells are 
known to be BRAF-mutated cell lines harbouring the V600E mutation in the BRAF 
protein. Due to this mutation the cells are sensitive towards the BRAF- and MEK-
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inhibitors vemurafenib and trametinib, respectively. By treating melanoma cells with 
mithramycin A alone or in combination with vemurafenib or trametinib, I wanted to 
determine whether SETDB1-inhibition could increase the treatment efficacy. Cell viability 
assays with melanoma cells exposed to increasing concentrations of mit for 24h in 
combination with either 3 μM vemurafenib (mit+vem treatment) or 3 µM trametinib 
(mit+tra) showed that the combinatorial drug treatment induced more cell death than 
single drug-treatments (Figure 23A and 23B). A functional characterization of A375 and 
SK-HI-SETDB1 cells treated with SETDB1 inhibitor, BRAF/MEK inhibitors, and with a 
combination of all of them was done. Vem- and tra-treated cells showed a modest 
impairment of migratory and invasive capacity compared with the untreated ones, while 
the presence of mit for 24h triggered a functional regression of tumor cells (Figure 23C 
and 23D). As a conclusion, mithramycin A severely diminished the viability of melanoma 
cells expressing high amounts of SETDB1 and reduced their migrative and invasive 
capacity. Targeted therapies with MAPK inhibitors (vemurafenib and trametinib) in 
combination with mit showed an increased efficacy suggesting putative synergistic and 
multi-targeting mechanisms of action. 
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Figure 23: Treatment with mithramycin A in combination with BRAF-/MEK-inhibitors, strongly 
contributed to melanoma cell death and to an impairment of tumor cell features. A) Viability assay of 
A375 and SK-HI-SETDB1 melanoma cells treated with increasing doses of mit alone or in combination 
with sub lethal concentrations of vemurafenib (3 µM) or trametinib (3 µM). Cells showed a greater 
sensibility to the combined therapies after 24h. Viability of DMSO-treated (control) cells was set as 100%. 
B) A375 and SK-HI-SETDB1 mit IC50 (nM) related to the single treatment and in combination with vem and 
tra, for 24 hours. C) Quantification of the migration rate of melanoma cells. Cells were initially stimulated 
according to the established drug treatment conditions. After 8h, cells were scratched. Another 16h later 
the percentages of open gap area were defined. D) Transwell invasion assay performed with A375 and 
SK-HI-SETDB1 cells showing that the addition of 300 nM mit greatly reduced the invasive capacity of 
BRAF-mutated cell lines that were simultaneously treated with vemurafenib (mit+vem) or trametinib 
(mit+tra), compared to the same cells treated with the respective BRAF-inhibitor only.  
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5 Discussion 
 
The incidence and mortality rates of malignant melanoma have dramatically increased 
over the past decade. Well-established and FDA-approved melanoma treatments based 
on immunotherapies and targeted therapies achieved good clinical responses. 
Nonetheless, these therapeutic approaches are still limited by the presence of adverse 
effects related to poor drug specificity, lack of efficacy and development of resistance 
mechanisms. Therefore, identification of innovative treatment strategies represents the 
biggest challenge in this field. Melanomas exhibit high levels of complexity and 
intratumoral heterogeneity (Andor et al, 2016). Tumor initiation, progression and 
metastasis are all the result of multiple, concomitant molecular events leading to the 
alteration of numerous cell signaling pathways. A better understanding of novel cancer-
promoting mechanisms is essential to improve melanoma treatment options. Recently, 
some studies shed light on the contribution of epigenetic processes to 
melanomagenesis. In particular, the histone methyltransferase SETDB1 seems to play a 
pivotal role during melanoma progression. However, the precise mechanisms of action 
of SETDB1 are still unclear. 
In this study, I elucidated the functional role of SETDB1 in melanoma, showing that: i) 
SETDB1 acted as master regulator of an oncogenic transcriptional network, ii) SETDB1 
expression was associated with drastic changes of the epigenetic profile of melanoma 
cells, and iii) mithramycin A reduced cancer cell-specific features and induced death of 
melanoma cells by specifically targeting SETDB1. 
 
5.1 SETDB1 promotes melanoma progression by modulating the 
expression of specific downstream effectors 
 
Previous studies indicated an oncogenic role for SETDB1 in melanoma suggesting that 
this factor might be involved in cancer-related molecular processes. The first set of 
analyses examined the contribution of SETDB1 to inducing transcriptomic changes 
during melanoma tumorigenesis. Transcriptional profiling identified differentially 
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expressed genes following ectopic overexpression of SETDB1 in HT144 melanoma 
cells. Functional annotation revealed that many genes upregulated in SETDB1-
overexpressing cell lines were part of gene sets related to regulation of cell proliferation, 
cell motility and EMT. These genes have been found to be more strongly expressed in 
melanoma and other tumor cells, such as breast and prostate cancer (Schartl et al, 
2012) (Smit et al, 2016) (Yuan et al, 2015) (Ahmed et al, 2018). In silico interpretation of 
transcriptomic data suggested that high levels of SETDB1 induced the upregulation of 
multiple pro-tumorigenic factors in melanoma cells. 
The analysis of putative SETDB1 target genes was extended to a group of secreted 
oncoproteins, whose expression was induced by SETDB1. Alterations of the tumor cell 
secretome heavily contribute to tumorigenic processes and, for this reason, represent a 
hallmark of carcinogenesis (Paltridge et al, 2013). Differential expression analysis 
indicated that SETDB1 upregulation increased the expression of genes encoding 
secreted proteins. Deregulated factors included the matricellular protein THBS1, the 
granule protein SCG2, the cytokine IL6, matrix metalloproteases (MMP1 and MMP3) 
and chemokines (CCL2 and CXCL8). SCG2 is a member of the granin family. Peitsch et 
al. demonstrated that SCG2 is highly expressed in primary and metastatic melanoma 
and that it is implicated in a cellular mechanism promoting melanoma cell migration 
(Peitsch et al, 2014). The role of IL6, matrix metalloproteases and chemokines in 
melanoma progression has been extensively studied by several groups (Hoejberg et al, 
2012) (Moro et al, 2014) (Payne & Cornelius, 2002). In this work, I focused on the role of 
thrombospondin 1 (THBS1) as a putative downstream target of SETDB1. THBS1 
encodes for a multidomain glycoprotein belonging to the thrombospondin family. The 
THBS1 protein drives variegated effects in a wide range of tumors (Huang et al, 2017). 
In melanoma, THBS1 is expressed in mesenchymal-like cells and metastatic tumor 
biopsies. In this context, THBS1 enhances EMT, angiogenesis, pro-migratory, pro-
invasive and pro-metastatic activities (Jayachandran et al, 2014) (Borsotti et al, 2015). 
Moreover, THBS1 needs to bind to the CD47 receptor to promote melanoma metastasis 
dissemination (Jeanne et al, 2016). While the oncogenic functions of THBS1 have been 
elucidated widely, little is known about THBS1 regulation. SETDB1 gain- and loss-of-
function experiments showed that SETDB1 induced THBS1 expression in melanoma 
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cells, while SETDB1-knockdown resulted in decreased THBS1 levels. In addition to this, 
THBS1-knockdown in SETDB1-overexpressing melanoma cells impaired the migration 
capacity distinctly, supporting the hypothesis that THBS1 plays a role in establishing the 
SETDB1-induced migratory phenotype. This newly identified SETDB1-THBS1 axis was 
next examined in primary and metastatic melanoma tumor biopsies. 
Immunohistochemistry combined with tissue microarray analysis represents a powerful 
tool which allows to efficiently evaluate and compare the expression patterns of putative 
candidate factors in a large cohort of patients-derived samples, providing meaningful 
insights into the identification of predictive and prognostic tumor markers (Jawhar, 2009) 
(Schmidt et al, 2009). SETDB1 is frequently overexpressed in clinical melanoma 
samples (Ceol et al, 2011) (Miura et al, 2014). Patients included in this study were 
classified based on their SETDB1 IHC score. In line with previous works (Jayachandran 
et al, 2014) (Borsotti et al, 2015), THBS1 was found to be highly expressed in most of 
the analyzed melanoma tissues. Intense THBS1 signals were predominantly detected in 
cancer specimens with high SETDB1 expression, while patients characterized by low 
levels of SETDB1 expression also exhibited weak THBS1 signals. Hence, the co-
expression of SETDB1 and THBS1 in tumor biopsies strongly corroborated their close 
connection. By further exploring SETDB1 and THBS1 expression patterns in primary 
melanoma tumor tissues, I could observe that both factors are heterogeneously 
distributed within the same lesion, showing more pronounced signals in outer regions 
corresponding to the invasive front of a tumor (Bryne et al, 1998). Several studies 
showed that accumulation and activation of tumorigenic factors in the tumor invasive 
area is an important indication of an aggressive phenotype of a tumor (Hofmann et al, 
2003) (Mitsui et al, 2014) (Staub et al, 2007). In light of this, SETDB1 and THBS1, both 
identified as promoters of cell invasion, localize at the invasive fronts of melanomas. The 
colocalization of SETDB1 and THBS1 might represent a valid prognostic marker for 
advanced melanomas. 
By analyzing differentially expressed genes in SETDB1 OE cell lines I identified several 
genes, whose expression seems to be negatively affected by SETDB1. These factors 
can be functionally classified into two different groups: melanocyte differentiation 
markers and metabolic enzymes. Pro-differentiation factors found downregulated 
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following overexpression of SETDB1 in melanoma cells included tyrosinase (TYR), 
tyrosinase-related protein 1 (TYRP1), dopachrome tautomerase (DCT, TRP2) and the 
premelanosome (PMEL17, gp100) proteins. These proteins are known as regulators of 
melanocyte development and functions (Guyonneau et al, 2004) (Raposo & Marks, 
2007). In melanoma, the role of melanocytic markers is still under debate: while several 
studies report a loss of DCT, TYR and TYRP1 during melanoma progression 
(Lenggenhager et al, 2014) (Lee et al, 2018a) (Fang et al, 2002), others report that 
melanoma subpopulations can express these factors (Aris et al, 2012) (Pak et al, 2004). 
However, the expression of pro-differentiation markers positively correlates with a 
favorable clinical outcome in patients with metastatic melanoma (Takeuchi et al, 2003). 
In this study, the SETDB1-dependent expression of DCT in melanoma cells was 
examined. In SETDB1 OE melanoma cells, characterized by a more proliferative and 
aggressive behavior, DCT expression was strongly reduced, whereas high levels of DCT 
were observed in melanoma cell lines with low endogenous SETDB1 expression. This 
negative correlation suggests that SETDB1-positive cell populations possess might be 
less differentiated. The metabolic factors aldolase C (ALDOC) and apolipoprotein E 
(APOE) were also silenced upon SETDB1 induction. ALDOC and APOE mediate anti-
tumorigenic effects: ALDOC expression negatively correlates with migration and 
invasion properties of oral squamous cell carcinoma (OSCC) cells (Li et al, 2016) and it 
is recruited as an effector by the metastasis suppressor NME1 in melanoma 
(Pamidimukkala et al, 2018). APOE acts as anti-angiogenic and anti-metastatic factor 
inducing melanoma regression (Pencheva et al, 2012). Hence, the findings of this study 
suggest that SETDB1 induced drastic transcriptomic changes characterized by the 
concomitant activation of a genes associated with augmented tumorigenesis and tumor 
progression and, on the other side, the repression of pro-differentiation/ anti-tumorigenic 
factors.  
Knowing about SETDB1-mediated gene regulatory effects, further experiments were 
performed with the purpose to identify mechanisms of action of SETDB1 in greater 
detail. In particular, the aim was to ascertain if SETDB1 functions were related to its 
catalytic SET domain, which modulates the HMT activity of SETDB1. Moreover, the SET 
domain is directly involved in protein-protein interactions (Yeates, 2002). In order to 
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study the role of the SET domain, additional experiments were performed with a 
SETDB1-variant lacking the HMT activity due to two amino acid exchanges. Point 
mutations in the SET domain may lead to a complete inactivation of SETDB1, either by 
directly changing the catalytically active amino acid residues or by altering the structural 
conformation of the whole protein. Several somatic mutations of the SET domain of 
SETDB1 have been previously identified in patients. These mutations include missense 
alterations (G869E, C911F, S947C) and an in-frame deletion (F1250del). G869E 
resulted in a complete inactive protein (Kang et al, 2016). Ceol et al. described the 
effects of two amino acid substitutions (H1224K and C1226A) in a melanoma zebrafish 
model: mutated SETDB1 did not completely lose the methylation activity, since it was 
still recruited by other H3K9 HMTs, forming a multimeric complex (Ceol et al, 2011). 
However, this study showed that the H1224K/C1226K substitutions in the SET domain 
heavily impacted the effects of SETDB1 on human melanoma. First, a severe reduction 
of total H3K9me3 levels was observed in melanoma cells expressing the mutated 
SETDB1 variant, in comparison to cells expressing wild-type SETDB1. Moreover, whole-
transcriptome analysis revealed that genes deregulated upon expression of SETDB1 
where not deregulated in response to the expression of HC/KA SETDB1. HC/KA 
SETDB1 OE cells exhibited reduced THBS1 and increased DCT expression. This 
finding strongly confirmed that THBS1 and DCT served as SETDB1 target genes, and 
moreover suggested that the SET domain is responsible for THBS1 and DCT regulation. 
Integration of gene expression data with functional annotations unveiled the 
deregulation of biological processes related to cancer development and invasiveness, 
showing a negative correlation with the expression of the mutated SETDB1 variant. On 
the other hand, inactivation of the catalytic activity of SETDB1 abolished the repression 
of pro-differentiation genes by wild type SETDB1. Functional experiments validated 
these observations. Scratch migration and transwell invasion assays constitute effective 
and reliable in vitro approaches to assess the motile properties of tumor cells (Kramer et 
al, 2013). HC/KA SETDB1 OE cells exhibited limited migratory and invasive capacities 
compared with cells overexpressing the wild type SETDB1. Therefore, SET domain 
disruption led to an impairment of melanoma cell aggressiveness. Surprisingly, analysis 
of the proliferative rate of tumor cells did not reveal significant discrepancies in relation 
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to the mutational status of SETDB1. The lack of an anti-proliferative effect despite the 
concomitant reduction of cell migration and invasion may be the consequence of 
melanoma phenotype switching. In tumor cells, proliferation and invasion are uncoupled 
functions defined by different gene signatures (Hoek et al, 2008). Although SETDB1 
expression has been linked to increased cell proliferation (Orouji, 2016), the data 
presented here suggest that the catalytic activity of the SET domain of SETDB1 mainly 
affects cell motility, while proliferative effects might be regulated by the other functional 
domains of SETDB1, such as MBD and tudors. 
 
5.2 Analysis of epigenetic alterations in melanoma cells following SETDB1 
dysregulation 
 
Epigenetic regulators are often involved in cancer progression, either directly acting as 
transcription factors or through the modulation of epigenetic marks, providing the 
substrate for the transcriptional machinery. SETDB1 mediates the trimethylation of 
lysine residue number 9 (K9) on histone H3. H3K9me3 is typically known as a 
repressive chromatin mark. Nonetheless, SETDB1 was shown to promote the 
expression and secretion of pro-tumorigenic proteins. In order to address these 
apparently contradictory facts, the next set of analyses aimed at detecting and 
characterizing SETDB1-induced epigenetic alterations in cancer cells. ChIP sequencing 
was performed to investigate the whole-genome chromatin structure in melanoma cells. 
ChIP-seq analyses have greatly contributed to the identification of novel key factors 
deregulated in different cancer types (Zhang et al, 2014) (Raj et al, 2017). This study 
mainly focused on the detection of histone marks related to regulatory processes. As 
expected, ChIP-seq analysis of H3K9 trimethylation in melanoma cells proved that 
SETDB1 was the major regulator of genome-wide H3K9me3 distribution: increased 
SETDB1 levels resulted in an enrichment of chromatin sites marked by H3K9me3. This 
was in accordance with H3K9me3 protein levels detected in SETDB1 OE cells. 
Increased global H3K9me3 levels correlate with malignant transformation, 
dedifferentiation, pro-invasive behavior, drug tolerance and poor clinical outcome in 
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several cancer types, such as colorectal cancer, liposarcoma, melanoma and salivary 
adenoid cystic carcinoma (Yokoyama et al, 2013) (Keung et al, 2015) (Al Emran et al, 
2018) (Xia et al, 2013). Conversely, SETDB1 knockdown strongly impaired the genome-
wide abundance of H3K9me3 marks. It has been previously reported that tumor cells 
with reduced H3K9me3 levels acquire a differentiated phenotype or undergo apoptosis 
(Lee et al, 2018b) (Lu et al, 2018). Taken together, the abundance of the H3K9me3 
mark could serve as an important prognostic factor in cancer. 
While SETDB1 expression showed a positive correlation with H3K9me3 in melanoma 
cells, an opposite trend was observed for the levels of monomethylated lysine 4 on 
histone H3 (H3K4me1) at the THBS1 promoter: increased H3K4me1 marks were 
observed upon SETDB1-silencing. The H3K4me1 mark is preferentially located at 
promoter and enhancer regions of active genes. H3K4 mono– and trimethylated forms 
are normally mutually exclusive and show differential distribution patterns in regulatory 
regions: while H3K4me3 marks are restricted to areas proximal to transcription start 
sites (TSS), H3K4me1 shows a widespread distribution on the entire promoter region 
and beyond the TSS (Cheng et al, 2014). H3K4me3-enriched active promoters show 
reduced levels of H3K4me1. Moreover, promoter-associated H3K4me1 marks modulate 
gene repression (Heintzman et al, 2007) (Cheng et al, 2014). A recent work conducted 
by Perner et al. exploited computational approaches to predict interactions between 
histone modifiers and chromatin marks. The data showed that a negative correlation 
exists between SETDB1 and H3K4me1, indicating that either SETDB1-chromatin 
association fails in the presence of H3K4me1 or, alternatively, H3K4me1-genome 
enrichment is reduced by SETDB1 expression (Perner et al, 2014). In light of this, 
H3K4me3 ChIP-seq data suggest that SETDB1 regulated the expression of its target 
genes via the modulation of H3K4me1 epigenetic marks at crucial regulatory sites.  
The mechanism behind the SETDB1-mediated alteration of H3K4me1 still remains 
poorly understood. Epigenetic effects induced by SETDB1 might be directly carried out 
by other chromatin regulators, which would act as SETDB1 interaction partners. The 
H3K4me1-enriched region at the THBS1 promoter represents a CTCF binding motif 
frequently occupied by the transcriptional repressor CTCF in a large number of cell 
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types (source: UCSC, https://genome.ucsc.edu/). CCCTC-binding factor (CTCF) is a zinc 
finger protein involved in numerous molecular processes related to maintenance of 
chromatin architecture and regulation of gene expression (Kim et al, 2015). Several 
histone modifications, including H3K4me1, localize in CTCF genomic sites and are 
involved in CTCF-mediated genomic mechanisms, such as chromatin looping and 
condensation (Barski et al, 2007) (Weth et al, 2014) (Oti et al, 2016). Interestingly, Jiang 
et al. reported that SETDB1 is essential for maintaining the correct 3D genome structure 
in mouse and human neuronal cells. SETDB1-silencing causes disruption of 
topologically associated domains (TADs), large genomic structures crucial for chromatin 
conformations (Dixon et al, 2016) and, strikingly, transcriptomic dysregulation of TAD-
associated genes. Mechanistically, it was observed that TAD alterations caused by 
SETDB1 ablation were accompanied by aberrant CTCF genomic binding (Jiang et al, 
2017). Based on these observations, it is quite possible that CTCF may be implicated in 
epigenetic alterations induced by SETDB1 in melanoma.  
 
5.3 Effects of the SETDB1 inhibitor mithramycin A on melanoma cells  
 
Development of novel strategies for targeted therapy represents a growing area of 
cancer research. Over the past few years, considerable research efforts have been 
devoted to the identification and characterization of key factors that could serve as 
therapeutic targets. 
Given its relevant oncogenic role, targeting SETDB1 may represent a promising 
therapeutic option for melanoma treatment. The DNA-binding antibiotic mithramycin A 
(mit) suppresses SETDB1 expression by modulating SP-1 protein activity. Mit exhibits 
potent antitumor effects in several types of cancer (Ream et al, 1968) (Dutcher et al, 
1997) (Choi et al, 2014). Moreover, mit was included in a phase II clinical trial for the 
treatment of lung cancer, esophageal cancer, breast cancer, mesothelioma and 
gastrointestinal neoplasms (NCT01624090). Lung cancer cells treated with mit show 
reduced proliferation and decreased levels of SETDB1. Notably, mit treatment is only 
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effective against lung cancer cell lines with high SETDB1 gene amplification and 
expression levels (Rodriguez-Paredes et al, 2014). In this study, mit was tested on 
melanoma cell lines. Cell viability assays demonstrated that melanoma cells with extra 
SETDB1 gene copies (SK-HI-SETDB1) and elevated levels of SETDB1 expression 
(A375) were particularly sensitive to mit treatment, whereas non-malignant cells, like 
dermal fibroblasts, as well as SETDB1-silenced melanoma cells were not affected by mit 
exposure. Furthermore, mit treatment abrogated SETDB1 expression in melanoma cells 
in a dose-dependent manner. These findings completely confirmed the inhibitory effects 
of mit observed in lung cancer cell lines.  
Tumor cells exposed to anticancer drugs display deep alterations in morphology and 
function. Mit treatment led to drastic morphological changes of melanoma cells, 
exhibiting larger nuclei and less-pronounced membrane protrusions. Previous 
experiments revealed that ectopic expression of SETDB1 induced melanoma cells to 
acquire a more elongated, spindle-shaped morphology (Orouji, 2016). It has been 
reported that such morphological changes are predictive of an enhanced aggressive 
tumor cell behavior (Friedl & Alexander, 2011). Mit treatment seemed to revert this 
morphology. Changes of the shape of mouse and human melanoma cell were observed 
also upon treatment with doxorubicin and MAPKi (Mariani & Supino, 1990) (Powell et al, 
2016). 
In melanoma, BRAFV600E-targeting therapy changes the transcriptome (Wongchenko et 
al, 2017) and secretome (Obenauf et al, 2015) of tumor cells. In a similar way, mit 
induced alterations of gene expression and protein secretion in melanoma cells. The 
pharmacological downregulation of SETDB1 with mit confirmed the downregulation of 
pro-tumorigenic and pro-invasive factors and increased levels of pro-differentiation and 
metabolic markers observed in SETDB1 knockdown or HC/KA SETDB1 OE cells. Once 
again, SETDB1 deregulation resulted in a bivalent gene expression pattern affecting 
melanoma cell properties and behavior.  
In this study, the secretome of melanoma cells was analyzed with regard to SETDB1 
expression levels. Profiling of the secretomes indicated that SETDB1 inhibition limited 
the release of several oncoproteins. Amongst the factors whose secretion was impaired 
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by mit treatment I could detect CCL2, a major driver of melanoma progression and 
metastasis (Payne & Cornelius, 2002), IL8, an inducer of angiogenesis found highly 
expressed in melanoma metastasis (Singh & Varney, 2000), and MMP8, which has 
been found to be frequently mutated and overexpressed in melanoma (Giambernardi et 
al, 2001) (Palavalli et al, 2009). Contrary to expectations, the level of secreted THBS1 
was not affected by SETDB1 inhibition. This observation could be attributed to the 
multifunctional nature of the THBS1 protein due to its multimodular structure, which 
allows THBS1 to participate in different intra- and extracellular signaling pathways (Sid 
et al, 2004) (Resovi et al, 2014). In light of this, I speculated that endogenous THBS1 
intracellular interactions are involved in melanoma progression. 
THBS1 repression in mit-treated melanoma cells was shown to correlate with increased 
H3K4me1 at its promoter. Hence, mit also contributes to epigenetic effects. The impact 
of mit on epigenetic mechanisms has been previously reported by Banerjee et al., who 
observed that mit directly interacts with histone proteins and modulates histone 
modifications related to gene transcription, such as H3K18 acetylation (Banerjee et al, 
2014).  
As opposed to THBS1, DCT expression was strongly enhanced by mit exposure. DCT 
expression and DCT gene promoter activity are increased upon mit treatment, proving 
that SETDB1-mediated DCT regulation occurs at the transcriptomic level. This finding 
suggests that SETDB1-silencing induced melanoma tumor regression and the activation 
of a transcriptional program related to differentiation. ChIP-seq data analysis did not 
reveal any epigenetic alterations in the regulatory region of the DCT gene. I conclude 
that alternative genetic or epigenetic mechanisms, influenced by SETDB1, modulate 
DCT expression. 
 
The investigation of the effect of SETDB1-inhibition on the functional properties of 
melanoma cells showed that mit treatment strongly suppressed their migration and 
invasion capacity. Mit modulate similar effects in several cancers: in glioma mit 
represses the expression of migration-related factors, impairing the glioma cell migratory 
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capacities; in salivary adenoid cystic carcinoma, mit limits cell invasion and EMT, while 
mit treatment reduces invasive and metastatic potential in lung cancer cells (Seznec et 
al, 2011) (Li et al, 2017) (Lin et al, 2007). In addition to wound healing and transwell 
assays, a 2D invasion model was used to better characterize melanoma cell motility. In 
vitro 2D invasion systems aim at simulating the conditions found in solid-tumor 
microenvironment, like the interaction with stromal cells (fibroblasts) and soluble factors 
released by fibroblasts (Nnetu et al, 2012). Melanoma cells activate fibroblasts which in 
turn sustain tumor cell growth, malignant transformation and drug resistance (Flach et al, 
2011). In the presence of mit, however, melanoma cells which were in direct contact with 
fibroblasts still failed to migrate and invade the fibroblast layer. 
Lastly, I evaluated the anti-tumorigenic effect of SETDB1-inbition in combination with 
established inhibitors of components of the MAPK pathway that is frequently 
deregulated in melanoma. BRAF- and MEK-inhibitors lead to melanoma cell death and 
tumor regression, resulting in positive clinical responses and improved outcomes. 
However, treatment with these inhibitors shows limited efficacy due to acquired 
mechanisms of drug resistance. Development and establishment of combinatorial/multi-
targeted therapeutic strategies able to circumvent drug resistance represents the current 
challenge in melanoma research. Drug-response experiments revealed that mit, in 
combination with vemurafenib or trametinib, cooperatively promoted anti-proliferative, 
anti-migratory and anti-invasive effects. Furthermore, targeting SETDB1 mostly 
enhanced anti-tumorigenic effects in combinatorial treatments, whereas treatment with 
single MAPK inhibitors did not show any strong impairment of the migration and invasion 
capacity of melanoma cells. Taken together, my data suggests that combinatorial 
treatment of melanoma cells with mithramycin A and vemurafenib or trametinib could be 
a much more potent and more effective therapeutic option compared to single treatment 
with BRAF-inhibitors alone. 
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6 Conclusions 
 
The present work aimed at providing a better understanding of the role and the functions 
of the histone methyltransferase SETDB1 in melanoma. Previous studies indicated that 
SETDB1 acts as major driver of melanoma progression. Melanoma cell lines and clinical 
tumor biopsies exhibit aberrant SETDB1 amplification and expression, and high levels of 
SETDB1 correlate with an aggressive phenotype of melanoma cells. Nevertheless, the 
mechanistic role of SETDB1 in the context of melanoma was largely unknown. 
Here, I present data indicating that SETDB1 exerts its oncogenic functions during 
melanoma progression through regulating the transcription of downstream targets and 
altering epigenetic mechanisms (Figure 24A). On the basis of my findings one can 
propose a model where SETDB1 exerts relevant transcriptomic effects in melanoma, in 
particular as activator of pro-tumorigenic factors, such as THBS1, and as a repressor of 
melanocyte-specific genes related to differentiation, like DCT. I conclude that the pro-
tumorigenic effects mediated by SETDB1 during melanoma progression are the 
consequences of the activation of the newly identified SETDB1-centered regulatory 
network. Abolishment of the catalytic activity of SETDB1 totally abrogated the SETDB1-
mediated oncogenic effects in melanoma cells. 
This project also investigated the variations in the epigenetic landscape in melanoma 
cells. Findings of this work demonstrated that SETDB1 drove drastic epigenetic 
changes. SETDB1 dysregulation resulted in alterations of global H3K9me3 and local 
H3K4me1 mark distribution. In particular, differential H3K4me1 enrichment patterns 
modulate the expression of the SETDB1 target gene THBS1.  
Exposure of melanoma cells to the SETDB1 inhibitor mithramycin A (mit) indicates that 
they are sensitive to this potent antitumor drug widely used in clinical studies on cancer 
treatment. Mit effectively suppressed the expression of SETDB1 and induced changes 
at the transcriptomic, epigenetic, morphological and functional level. To conclude, 
SETDB1 inhibition enhanced the efficacy of established MAPKi therapies against 
melanoma (Figure 24B). In conclusion, this work supports the central role of SETDB1 
 
93 
 
as a key regulator of melanoma progression and as a promising candidate target for 
treating advanced melanoma. The development of novel therapeutic strategies aiming at 
selectively targeting SETDB1 expression and functions may result in significant clinical 
benefits. 
 
 
 
 
Figure 24: Schematic overview of the mechanistic role of SETDB1 in melanoma cells.A) SETDB1 
expression induces drastic transcriptomic, epigenetic and functional effects. SETDB1 induces the 
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expression of oncogenic factors, such as THBS1, while it limits the expression of anti-metastatic and pro-
differentiation genes, like DCT. The levels of the histone methyltransferase SETDB1 positively correlate 
with the global enrichment of its histone modification target, H3K9me3. SETDB1 expression strongly 
affects the monomethylated H3K4 distribution at THBS1 regulatory sites, determining in this way the 
transcriptional regulation of THSB1. The activation of SETDB1-centered regulatory network in melanoma 
cells results in the acquisition of tumor aggressive properties, like cell migration and invasion. The 
oncogenic role of SETDB1 in melanoma is dependent by the activity of its catalytic SET domain. B) The 
antitumor antibiotic mithramycin A selectively inhibits SETDB1 expression in melanoma cells, reverting in 
this way all the SETDB1-mediated pro-tumorigenic effects: melanoma cells under mit treatments exhibit 
low expression of SETDB1 target oncogenes and high levels of genes downregulated by SETDB1 and 
involved in cell differentiation or cell metabolism mechanisms. THBS1 downregulation in SETDB1 high-
expressing cells is accompanied by increased levels of H3K4me1 surrounding THBS1 promoter region. 
SETDB1 inhibition results in a reduction of MMP8, IL8 and CCL2 protein secretion. Melanoma cells 
treated with mit show reduced cell viability, migration and invasion. Mit effects are increased in 
combinatorial treatments with MAPK inhibitors vemurafenib and trametinib. 
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Table 1: IPA functional annotations of cancer-related biological functions predicted to be increased (positive 
z-score) in SETDB1 OE HT144 melanoma cell lines, compared with control (EV HT144) cells. 
Diseases or 
Functions 
Annotation 
Predicted 
Activatio
n State 
z-score p-Value Molecules 
Growth of tumor Increased 3,231 1,87E-11 ANXA2,AXL,BIRC2,CCL2,CD24,CEACAM1,CXCL8,CYGB,DCT,DKK1 
Invasion of tumor Increased 2,651 1,77E-10 ANXA2,APOE,CCL2,CD24,CEACAM1,HMOX1,HYAL1,IL6,KLF4, 
MMP1 
Invasion of tumor 
cells 
Increased 2,254 2,78E-08 CD24,CEACAM1,HMOX1,IL6,KLF4,MMP1,MMP3,NRP1,PTGS2, 
TGFA 
Metastasis Increased 3,138 0,000000257 APOE,AXL,CCL2,CD24,CPA4,CXCL8,DKK1,GYG2,HMOX1,IL6 
Advanced 
malignant tumor 
Increased 3,138 0,000000913 APOE,AXL,CCL2,CD24,CPA4,CXCL8,DKK1,GYG2,HMOX1,IL6 
Metastatic solid 
tumor 
Increased 2,153 0,000000956 AXL,CCL2,CD24,CPA4,CXCL8,DKK1,GYG2,HMOX1,IL6,MMP1 
Advanced 
malignant solid 
tumor 
Increased 2,153 0,00000264 AXL,CCL2,CD24,CPA4,CXCL8,DKK1,GYG2,HMOX1,IL6,KLF4 
Progression of 
tumor 
Increased 2,18 0,0000249 ANXA2,APOE,AXL,CXCL8,IL6,MMP1,NRP1,PTGS2,THBS1,TUBB4A 
Metastasis of cells Increased 2,01 0,0000256 CCL2,CD24,CXCL8,HMOX1,LAMA5,MMP1,MMP3,PTGS2,TGFA, 
THBS1 
Metastasis of 
tumor cell lines 
Increased 2,01 0,0000769 CCL2,CD24,CXCL8,HMOX1,LAMA5,MMP1,MMP3,PTGS2,THBS1 
Invasion of tissue Increased 2,606 0,000217 AXL,CCL2,CD24,CXCL8,EVL,MMP1,MMP3,NRP1 
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Table 2: Top-enriched DAVID biological terms related to downregulated genes in SETDB1 OE HT144 
melanoma cell lines compared with control (EV HT144) cells. 
Category Term p-Value Genes 
GOTERM_BP_DIRECT GO:0042438: melanin 
biosynthetic process 
1.03E-07 DCT, TYRP1, TYR, PMEL, CITED1 
UP_KEYWORDS Melanin biosynthesis 9.48E-07 DCT, TYRP1, TYR, PMEL 
UP_SEQ_FEATURE signal peptide 1.15E-05 TF, TYRP1, FXYD3, A2M, IL17RD, PCOLCE, DCT, IGSF11, 
TYR, APOE, BCHE, SERPINA5, SERPINA3, FGL2, 
CEACAM1, PLTP, PI15, MAG, HYAL1, RNASE1, PMEL, 
MGP, NBL1, LAMA5, FKBP14, FCRLA 
UP_KEYWORDS Secreted 1.57E-05 HAPLN1, HYAL1, TF, A2M, RNASE1, PMEL, TNFSF14, 
MGP, PCOLCE, NBL1, BCHE, LAMA5, APOE, SERPINA5, 
SERPINA3, FGL2, CEACAM1, PLTP, PI15 
INTERPRO IPR002227:Tyrosinase 3.18E-05 DCT, TYRP1, TYR 
INTERPRO IPR008922:Uncharacterise
d domain, di-copper 
centre 
3.18E-05 DCT, TYRP1, TYR 
UP_KEYWORDS Signal 3.66E-05 TF, TYRP1, FXYD3, A2M, IL17RD, PCOLCE, DCT, IGSF11, 
TYR, APOE, BCHE, SERPINA5, SERPINA3, FGL2, 
CEACAM1, PLTP, PI15, MAG, HYAL1, RNASE1, PMEL, 
MGP, MSRB2, NBL1, LAMA5, FKBP14, QPRT, FCRLA 
UP_SEQ_FEATURE topological 
domain:Lumenal, 
melanosome 
5.80E-05 DCT, TYRP1, TYR 
GOTERM_CC_DIRECT GO:0072562~blood 
microparticle 
1.54E-04 TF, A2M, HSPA2, BCHE, APOE, SERPINA3 
UP_KEYWORDS Glycoprotein 1.85E-04 TF, TYRP1, A2M, TNFSF14, IL17RD, PCOLCE, DCT, 
IGSF11, TYR, ACSL1, TSPAN10, APOE, BCHE, SERPINA5, 
SERPINA3, FGL2, CEACAM1, PLTP, PI15, HAPLN1, MAG, 
HYAL1, RNASE1, PMEL, GYG2, P2RX7, LAMA5, FKBP14 
GOTERM_CC_DIRECT GO:0042470~melanosome 3.64E-04 DCT, TYRP1, TYR, PMEL, RAB17 
GOTERM_CC_DIRECT GO:0070062~extracellular 
exosome 
5.62E-04 HYAL1, TF, A2M, FXYD3, RNASE1, MGP, PCOLCE, 
IGSF11, HSPA2, LAMA5, APOE, SERPINA5, RAB17, 
SERPINA3, AIF1L, QPRT, FGL2, CEACAM1, TUBB4A, 
GNG7, PI15 
GOTERM_CC_DIRECT GO:0033162~melanosome 
membrane 
5.94E-04 DCT, TYRP1, TYR 
GOTERM_CC_DIRECT GO:0043025~neuronal cell 
body 
6.35E-04 P2RX7, MYO10, APOE, RAB17, CYGB, PPARGC1A, 
TUBB4A 
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Table 3: IPA functional annotations of cell movement-related biological functions predicted to be decreased 
(negative z-score) in HC/KA SETDB1 OE HT144 melanoma cell lines, compared with control (SETDB1 OE 
HT144) cells. 
 
 
Diseases or 
Functions 
Annotation 
 
 
Predicted 
Activation 
State 
 
 
p-Value 
 
 
z-score 
 
 
Molecules 
Migration of 
cells 
Decreased 1,8E-10 -2,204 A2M,ABCB4,ADA,ADAM19,AGT,AIM2,ALPP,ANXA2,AXL,BCAR3 
Invasion of 
tumor cell 
lines 
Decreased 2,12E-08 -2,107 A2M,AGT,AXL,BCAR3,CAV1,CCL2,CCND1,CD151,CD24,CSE1L 
Cell 
movement of 
endothelial 
cells 
Decreased 4,81E-08 -3,041 AGT,ANXA2,AXL,CAV1,CCL2,CD151,CXCL1,CXCL8,DKK1,EFNB2 
Migration of 
tumor cells 
Decreased 6,71E-08 -3,249 CAV1,CCL2,CD151,COL4A3BP,CSE1L,CSF2RA,CXCL1,CXCL8,FGFR
4, 
GSN 
Cell 
movement of 
tumor cell 
lines 
Decreased 7,29E-08 -2,161 A2M,AGT,ANXA2,AXL,BCAR3,BRK1,CAV1,CCL2,CCND1,CD151 
Migration of 
endothelial 
cells 
Decreased 7,73E-08 -2,724 AGT,ANXA2,AXL,CAV1,CCL2,CD151,CXCL1,CXCL8,DKK1,EFNB2 
Migration of 
tumor cell 
lines 
Decreased 0,00000013
3 
-2,036 A2M,AGT,ANXA2,AXL,BCAR3,BRK1,CAV1,CCL2,CCND1,CD151 
Migration of 
cancer cells 
Decreased 0,00000039
3 
-2,944 CAV1,CCL2,CD151,COL4A3BP,CSE1L,CSF2RA,CXCL8,FGFR4,GSN, 
HRAS 
Cell 
movement of 
prostate 
cancer cell 
lines 
Decreased 0,00000271 -2,234 ANXA2,AXL,CAV1,CD151,CXCL8,GDF15,HMOX1,HRAS,ID1,IL6 
Cell 
movement of 
tumor cells 
Decreased 0,00000379 -2,621 CAV1,CCL2,COL4A3BP,CSF2RA,CXCL8,FGFR4,GSN,HRAS,IL6,LAM
A5 
Movement of 
vascular 
endothelial 
cells 
Decreased 0,000035 -2,528 ANXA2,CD151,CXCL1,CXCL8,DKK1,EFNB2,F11R,ID1,IL24,LEP 
Invasion of 
melanoma cell 
lines 
Decreased 0,0000445 -2,156 CD151,CXCL8,LAMA5,MITF,MMP1,MX1,POU3F2,PTGS2,RND3 
Cell 
movement of 
cancer cells 
Decreased 0,0000555 -2,65 CAV1,CCL2,CSF2RA,CXCL8,GSN,HRAS,IL6,LAMA5,NRP1,THBS1 
Chemotaxis Decreased 0,000348 -2,531 A2M, AGT,ANXA2,AXL,CAV1,CCL2,CCND1,CD151,COL4A3BP, 
CSF2RA 
Homing of 
cells 
Decreased 0,000409 -2,667 A2M,AGT,ANXA2,AXL,CAV1,CCL2,CCND1,CD151,COL4A3BP, 
CSF2RA 
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